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ABSTRACT 
Penny M. Anders: Modulation of Signal Transduction and Transformation by 
Kaposi’s Sarcoma-Associated Herpesvirus 
(Under the direction of Blossom Damania) 
 
 Kaposi’s sarcoma associated-herpesvirus (KSHV) is a double-strand DNA 
gamma herpesvirus that establishes lifelong latent infection in the human host. 
KSHV infection is associated with several cancers including the endothelial cell 
cancer, Kaposi’s sarcoma (KS); and two B-cell lymphomas, primary effusion 
lymphoma (PEL) and multicentric Castleman’s disease. This dissertation focuses on 
the importance of cellular signal transduction pathways in KSHV-associated cancers 
and focuses on two KSHV viral proteins, K1 and vPK, that modulate these signaling 
pathways. 
KSHV encodes over 100 genes including many proteins that alter signaling 
pathways to create a cellular milieu that promotes survival of the virally infected cell. 
The PI3K and MAPK signaling pathways are aberrantly active in PEL and other non- 
Hodgkin lymphomas (NHL), and are important for PEL survival. Because there is 
always a need for new effective therapies to treat NHL, which includes KSHV-
infected PEL, we sought to evaluate the effectiveness of dual inhibition of the PI3K 
and MAPK signaling pathways in killing NHL cells. We concluded that dual inhibition 
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of both pathways was no more effective at reducing cell viability and tumor burden in 
vivo than inhibition of the PI3K pathway alone.  
Some viral proteins modulate host cellular proteins and thereby promote KSHV 
pathology. The KSHV K1 viral protein is thought to be a major contributor to KSHV-
induced oncogenesis since the expression of K1 has been shown to lead to 
transformation in vitro and to tumor development in vivo.  
We identified AMPKγ1 as a K1-associating protein, and the K1 N-terminus is 
important for association with AMPKγ1. AMPK is a metabolic regulator that responds 
to many types of cellular stress by regulating pathways to maintain energy 
homeostasis. We found that K1 expression gives cells a survival advantage when 
cells are stressed by serum starvation or when AMPK is inhibited, and that this 
survival advantage is dependent on K1’s association with AMPK. AMPK activity is 
also increased in K1-expressing cells following exposure to metabolic stress.  
Unlike K1, which is unique to KSHV, vPK (ORF36) is a viral serine/threonine 
kinase that is conserved among herpesviruses, underscoring the importance of this 
kinase in herpesvirus infection and KSHV biology. Our lab has found that vPK 
expression facilitates cellular transformation in vitro and that vPK phosphorylates 
ribosomal protein S6, a protein that is typically phosphorylated by S6 kinase and 
involved in protein synthesis. Thus far, our understanding of vPK function and its 
impact on the host has been based on data obtained from in vitro culture models. 
We sought to add novel insight into the function of vPK by evaluating the phenotype  
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of vPK in vivo. We found that naïve vPK transgenic mice have an activated immune 
system that is similar to immunized wild-type mice. Moreover, aged-vPK mice are 
more prone to lymphoma development than wild-type mice.  
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CHAPTER 1. INTRODUCTION 
OVERVIEW 
Kaposi’s sarcoma-associated herpesvirus (KSHV) or human herpesvirus-8 
(HHV-8) is the causative agent of the endothelial cancer Kaposi’s sarcoma (KS) and 
two B cell lymphomas, primary effusion lymphoma (PEL) and multicentric 
Castleman’s disease (MCD) [1-3]. These KSHV-associated diseases mainly occur in 
immune-suppressed individuals such as those who are HIV positive or who are 
organ transplant recipients although they can also occur in seemingly immune 
competent individuals.  KS is one of the most common cancers among sub-Saharan 
African men, and the most prevalent cancer in several countries in sub-Saharan 
Africa [4, 5].  
Treatment options for individuals with KS include antiretroviral therapy for HIV- 
positive individuals, therapies that boost the immune system, and/or excision of the 
KS lesion. Individuals with PEL typically are treated with CHOP (cyclophosphamide, 
doxorubicin, vincristine, and prednisone) chemotherapies. PEL is often resistant to 
chemotherapies and median survival following diagnosis is approximately 6 months 
[6]. Thus, effective therapies for KSHV malignancies are warranted and 
understanding the mechanisms that lead to KSHV-associated cancers may provide 
insight into the development of therapies to treat other cancers as well.  
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INTRODUCTION 
KSHV-ASSOCIATED CANCERS 
Kaposi’s sarcoma (KS) is a cancer that is believed to be of endothelial cell 
origin. During the 1980s, cases of Kaposi’s sarcoma started appearing in immune-
compromised individuals who were HIV positive. Although the KS lesion is typically 
viewed as a red patch that impacts the dermis on extremities, KS can also impact 
the mucosa and internal organs [7-9]. The KS lesion is composed of KSHV-infected 
spindle cells and a profusion of neovascular spaces [10]. The newly developed 
neovascular spaces are weak and allow leakage of fluids into the extravascular 
spaces, forming the characteristic KS red patch [9]. The KS lesions can progress 
from a patch, to a plaque, and then into a nodule. Although the KS lesion is 
composed of spindle cells, it is also filled with inflammatory cells including T, B and 
monocytic cells [11, 12].  
Inflammation has been found to play an integral part in the development and 
progression of KS. In the early stages of KS, there’s extensive inflammatory infiltrate 
including an influx of CD8+ and CD4+ -interferon-γ-producing T cells and the 
production of Th1-inflammatory cytokines [13]. Inflammatory cytokines re-activate 
KSHV from latency and stimulate endothelial cells to produce angiogenic factors 
thereby promoting KS progression [14]. In vivo, KS has also been found to localize 
to surgical sites or areas of skin trauma, further emphasizing the importance of 
inflammation to KS development [15, 16].  
The various forms of KS include classic KS, post-transplant KS, African KS and 
AIDS-KS. Classic KS, an indolent form, impacts elderly men of Mediterranean and 
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Eastern European origin.  Post-transplant KS impacts some transplant recipients 
and often resolves with the reduction or withdrawal of immunosuppressants although 
patients are then at risk for graft rejection [17]. African-KS, a more aggressive form 
that can impact the organs is found in children and young adults. AIDS-KS is the 
most aggressive form, causing lesions and impacting organs in HIV positive 
individuals. Anti-retroviral therapy has reduced the incidence of AIDS-KS [18]. 
Primary effusion lymphoma (PEL) is a monoclonal B cell lymphoma that is 
under the diagnostic umbrella of non-Hodgkin lymphoma [19]. It is a B cell-rich fluid 
localized to the body cavities. PEL occurs predominantly in HIV positive individuals. 
All PEL cells are latently infected with KSHV and can be cultured ex vivo [20, 21]  
Multicentric Castleman’s disease (MCD) is another B lymphoproliferative 
disease although it differs from PEL in that it is polyclonal and found as solid tumor 
affecting the lymphatic organs [22, 23]. MCD can occur in HIV positive and negative 
individuals, but when it is associated with KSHV infection, it usually occurs in 
individuals who are HIV positive [3].  
KAPOSI’S SARCOMA-ASSOCIATED HERPESVIRUS, HHV-8 
Chang et al. first isolated KSHV from KS lesions in 1994 [1]. KSHV is a double-
strand DNA gamma herpesvirus that has a genome of approximately 165 to 170 kb 
long that code for over 85 open reading frames and 12 micro RNAs [24-30]. The 
KSHV genome contains multiple open reading frames that are conserved among 
other herpesviruses, and genes K1-K15 that are unique to KSHV [7]. Similar to other 
gammaherpesviruses, KSHV can vacillate between latent and lytic programs 
although latency is the default program following primary infection.  
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KSHV can infect a variety of cell types in vitro and in vivo. In vivo, KSHV has 
been found in monocytes, B cells, endothelial/spindle cells, and epithelial cells [10, 
31-33]. Upon infection, KSHV typically establishes latency by forming an episome. 
The latency-associated nuclear antigen (LANA), binds the viral terminal repeats and 
tethers the viral genome to the host chromosome [7]. In this way, the viral genome is 
copied by host replication machinery and passed on to daughter cells during cell 
division.  
During latency, a subset of viral genes is expressed including LANA, v-FLIP, v-
Cyclin, kaposins A, B and C, v-IRF-3 as well as the twelve pre-microRNAs [34]. 
Although predominantly expressed during the lytic cycle, recent studies indicate that 
the proteins viral interleukin-6 (vIL-6) and K1 are expressed at low levels during 
latency as well [24, 35]. Upon reactivation, which can be induced in vitro with various 
compounds such as 12-O-tetradecanoylphorbol-13-acetate (TPA), histone 
deacetylase (HDAC) inhibitors, and TLR 7/8 ligands, KSHV enters the viral lytic 
cycle resulting in the production of infectious virions [24, 36]. 
Although KSHV is predominantly latent in KS spindle cells, PEL cells, and in 
MCD plasmablastic B cells [10], both latent and lytic phases appear to be important 
for KSHV pathology. Expression of latent genes generally promotes the survival of 
the infected cell and persistence of infection during cell division, and lytic gene 
expression results in the production of inflammatory cytokines, pro-angiogenic 
factors and viral proteins that subvert the host immune system and promote virion 
production.  
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KSHV LATENCY PROTEINS THAT PROMOTE TUMORIGENESIS 
The KSHV viral proteins and microRNAs expressed during latency are 
implicated in making major contributions to KSHV-induced cancers. Expression of 
the latency locus in B cells, which contains the genes for LANA, K13 (v-FLIP), a 
cellular cyclin D2 homolog (v-Cyclin), K12 (kaposin), and all viral microRNAs, in 
transgenic mice results in chronic mature B cell activation and B cell hyperplasia 
[37]. B cells are hyper-responsive to T-dependent antigen as well as 
lipopolysaccharide (LPS), resulting in increased germinal center responses and an 
increase in the number of plasma cells. B cells expressing the latency locus are 
poised and responsive to unrelated pathogen, making these cells susceptible to 
expansion; and yet only a fraction of the latency locus transgenic mice go on to 
develop lymphomas [37].  
Thus, the latency locus most likely contributes to, but is not the sole driver, of 
KSHV-induced oncogenesis. When transgenic mice expressing the latency locus are 
combined with mice containing a weak IgH Cα Myc allele, the latency locus/Myc 
mice develop lymphoma at a higher rate than the single transgenic mice expressing 
either the latency locus or Myc [38]. Again these data support the idea that the 
KSHV latency locus cooperates with host factors such as myc to promote 
oncogenesis. 
Several of the latency locus genes have oncogenic properties when expressed 
individually in mice. LANA transgenic mice have germinal center formation and 
splenic follicular hyperplasia [39] . A subset of the LANA transgenic mice actually 
develop various types of lymphoma [39] . Mechanistically, LANA may promote 
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tumorigenesis by altering cell cycle and/or survival. LANA binds to p53, and p53 
expressing cells have reduced sensitivity to p53-dependent apoptosis [24]. LANA 
interacts with the retinoblastoma protein (Rb) and increases E2F activity, suggesting 
that LANA inhibits Rb, promotes E2F activity and as a consequence promotes cell 
cycle progression [7].  
Another latency protein that appears to have a major impact on promoting 
cellular transformation is Fas-associated death domain-like IL-1 converting enzyme 
inhibitor protein (v-FLIP). In vitro, v-FLIP inhibits caspase-8 and facilitates activation 
of NF-κB [40]. Viral-FLIP expression has also been shown to transform rodent 
fibroblasts, and the transforming potential of v-FLIP is dependent on NF-κB 
activation [40]. The expression of v-FLIP under the major histocompatibility H2kb 
promoter leads to constitutive NF-κB activation in various lymphoid organs and an 
increased incidence of lymphoma of various subsets compared to controls [41]. 
Viral-FLIP expressing mice do not have impaired Fas-induced apoptosis [41].  
Expression of v-FLIP during different stages of B cell differentiation results in 
the development of B-cell lymphomas that have characteristics similar to PEL. 
These v-FLIP expressing mice also exhibit immune dysfunction in that they lack 
germinal center formation compared to controls following immunization [42]. Tumors 
from v-FLIP expressing mice contain cells exhibiting both B and macrophage/DC 
phenotypes as determined by markers specific for these cell types and flow 
cytometry, suggesting some sort of B cell plasticity in tumors from v-FLIP positive 
mice [42].  
 7 
Kaposin (K12), another latent gene, may have oncogenic potential. The kaposin 
gene results in the generation of kaposins A, B and C due to translation of kaposin 
mRNA from different sites of initiation [43]. Kaposin A expression can transform 
rodent fibroblasts and nude mice injected with Kaposin A expressing cell lines 
develop tumors [44].  
In this brief summary describing the oncogenic potential of some KSHV latent 
proteins, we can observe that KSHV latent proteins play a role in promoting cell 
survival by regulating cell cycle or by inhibiting apoptosis. Based on the in vivo 
models, we can also see that expression of some of these proteins alone or in 
concert with a cellular oncogene such as myc can result in tumor formation. Recent 
studies suggest that the expression of some latent and lytic proteins may not be 
assigned exclusively to either the latent or lytic program. The KSHV K1 protein was 
presumed to be expressed during the lytic cycle, but more recently has been found 
to be expressed during latency albeit at lower levels than during the lytic cycle [24, 
35, 45].  
K1 PROTEIN PROMOTES CELL SURVIVAL AND TUMORIGENESIS 
K1 is a 46-kDa transmembrane glycoprotein that is primarily expressed in the 
endoplasmic reticulum as well as the plasma membrane [46]. K1 contains and 
immunoglobulin-like ectodomain, a transmembrane region and a cytoplasmic tail 
that contains an immunoreceptor-like tyrosine-based activation motif (ITAM), which 
is similar to the signaling molecules in the B cell receptor signaling complex [47, 48]. 
It is thought that K1 is maintained in an activated state by oligomerization of the K1 
ectodomain and subsequent phosphorylation of the ITAM tyrosines by Src family 
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kinases [49]. K1 can interact with various SH2 (Src-Homology 2) containing 
signaling molecules, including Lyn, Syk, p85, PLCγ2, RasGAP, Vav, Grab 2 and 
SH2-containing tyrosine phosphatases 1/2 via the phosphorylated tyrosines in its 
ITAM [50]. Activation of K1 results in a signaling cascade leading to calcium 
mobilization, upregulation of the transcription factors NFAT and AP-1, and the 
production of inflammatory cytokines [50]. Expression of K1 induces the activation of 
phosphoinositide 3-kinase (PI3K) by phosphorylation of the p85 subunit of PI3K. 
Activation of PI3K leads to activation of downstream kinases including Akt and 
mammalian target of rapamycin (mTOR), which leads to the inhibition of forkhead 
transcription factor family and reduced cellular apoptosis [51]. K1 has also been 
shown to inhibit Fas-induced apoptosis [52, 53]. K1 may promote tumorigenesis by 
modulating signaling pathways that are important for cell survival and proliferation. 
 K1 is located in the KSHV genome at a position equivalent to the saimiri 
transforming protein (STP) of herpesvirus saimiri (HVS), a member of the 
rhadinovirus subgroup of gamma herpesvirues [54]. Replacement of oncogenic STP 
with K1 in HVS results in IL2-independent immortalization of T cells and the 
development of lymphoma in marmosets following infection with the K1 containing-
recombinant HVS [54]. K1 expression also transforms rodent fibroblasts and 
immortalizes primary endothelial cells [54, 55]. K1 transgenic mice develop 
lymphomas and sarcomas at low incidence [56].  
VIRAL PROTEIN KINASE (ORF36) 
KSHV encodes the serine threonine kinase ORF36 also known as viral protein 
kinase (vPK) that can be found in the nucleus and cytoplasm when expressed 
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ectopically in cells [57]. ORF36 shares limited homology with the protein kinases 
expressed by the other herpesviruses including UL13 (HSV), ORF47 (VZV), BGLF4 
(EBV), UL97 (HCMV), and U69 (HHV-6) [58]. However, there are also some 
differences. Viral PK appears to have diverse functions. Viral PK phosphorylates and 
activates the cellular targets, c-Jun N-terminal kinase (JNK), MKK4 and MKK7 as 
well as, the viral target K-bZIP, a transcription regulator that represses the latent/lytic 
switch protein, RTA (replication and transcription activator) protein [59, 60]. Kuny et 
al. also showed that vPK exhibits cellular cyclin dependent kinase-like activity, in that 
it can phosphorylate Rb thereby inactivating it and promoting cell cycle progression 
[57]. By binding to the activated form of interferon regulatory factor 3 (IRF-3), vPK 
also inhibits the anti-viral type I interferons [61].  
Our lab has recently shown that vPK resembles and mimics the activity of the 
cellular protein S6 kinase (S6KB1) [62]. S6KB1 is downstream in the PI3K/mTOR 
pathway and is phosphorylated by mTOR. Activated S6KB1 phosphorylates multiple 
targets some of which are involved in protein synthesis such as ribosomal S6 
protein, a protein that is part of the 40S ribosome; and eIF4B, a protein that is part of 
the translation pre-initiation complex [63]. Expression of vPK results in increased de 
novo protein synthesis, tubule formation and anchorage independent growth, 
compared to control cells, suggesting that vPK may be possess oncogenic 
properties [62].  
KSHV is predominantly latent in both PEL and KS although there may be 
periodic episodes of reactivation in a small percentage of infected cells. It is 
generally thought that latent proteins drive tumorigenesis; whereas, lytic proteins 
 10 
promote the production of chemokines and cytokines that support angiogenesis, and 
survival and growth of KSHV infected latent cells. Additionally, it is also possible that 
lytic proteins can be expressed in the absence of complete viral lytic replication. For 
example, vPK/ORF36 contains hypoxia responsive elements in its promoter, which 
may cause it to be expressed in isolation and in the absence of full-blown lytic 
replication [64, 65]. Thus, lytic proteins such as vPK, in addition to latent proteins, 
may be contributors to oncogenesis particularly in a changing cellular milieu. 
 
CELLULAR SIGNAL TRANSDUCTION PATHWAYS 
MAPK SIGNALING PATHWAY 
There are 4 major cascades of the mitogen-activated protein kinase (MAPK) 
pathway. Each cascade is comprised of multiple nodes that are activated 
sequentially, MAPKKK-MAPKK-MAPK [66]. In response to various stimuli such as 
growth factors, stress or cytokines; there is engagement of the cell surface receptor 
and this event initiates the activation of kinases that subsequently activate one or 
more cascades of the MAPK pathway. We will be focusing on the RAF (MAPKKK)-
MEK1/2 (MAPKK)-ERK1/2 (MAPK) cascade of the MAPK pathway, which is 
stimulated by growth factors, and involved in regulating cell survival and proliferation 
[66].  
PI3K SIGNALING PATHWAY  
The phosphoinositide 3-kinase (PI3K) pathway is constitutively active in many 
cancers and is involved in several major cellular processes including cell survival, 
proliferation, and metabolism [67]. PI3K is activated by engagement of receptor 
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tyrosine kinases and G-coupled protein receptors (GPCRs) and by small GTPases. 
The Class IA PI3Ks are composed of a p85-like regulatory subunit (p85α, p85β, and 
p55γ) and a p110 catalytic subunit (p110α, p110β, p110γ and p110δ) [67].  
When inactive, the p85 subunit prevents activation of the p110 subunit. Upon 
activation, the p85 subunit localizes to the plasma membrane thereby relieving p110 
so that it can phosphorylate PtdIns 4, 5-bisphosphate (PIP2) generating PtdIns (3, 4, 
5) P3 (PIP3). The serine threonine kinase, Akt, binds PIP3 via its pleckstrin homology 
(PH) domain resulting in translocation of Akt to the membrane. Akt is phosphorylated 
at Thr308 by phosphoinositide-dependent kinase-1 (PDK1); and for full activation, 
Akt is also phosphorylated at S473 on its C-terminus by mTOR complex 2 
(mTORC2) [68]. Akt phosphorylates many substrates including the proapoptotic 
factors Bad, GSK-3β, and the FOXO transcription family members resulting in the 
inhibition of these factors, thereby promoting cell survival and proliferation [69]. 
Activation of Akt also leads to the direct phosphorylation of tuberous sclerosis 2 
(TSC2), which releases its inhibitory effect on the serine/threonine kinase, 
mammalian target of rapamycin (mTOR) [70-73]. mTOR is part of two distinct 
complexes, mTORC1 and mTORC2. While both complexes contain mTOR, each 
complex responds to different upstream signals and initiates different downstream 
outputs. Mammalian TORC2 can phosphorylate and activate Akt thereby promoting 
cell survival, proliferation and metabolism [74]. Mammalian TORC1 responds to a 
multitude of cues including: growth factors, stress, amino acids, oxygen and energy 
status [74]. During favorable conditions, mTORC1 promotes anabolic processes 
such as protein and lipid synthesis and inhibits catabolic processes such as 
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autophagy [74]. Mammalian TORC1 directly phosphorylates eukaryotic translation 
factor 4E (eIF4E)-binding protein 1 (4E-BP1) and S6 kinase 1 (S6K1), and promote 
protein synthesis [74]. Unlike mTORC2, mTORC1 is rapapmycin-sensitive [75].  
 
KSHV AND ACTIVATION OF THE PI3K AND MAPK PATHWAYS 
The PI3K and MAPK pathways are activated early and appear important for 
KSHV infectivity. Binding of KSHV virions to integrins on the cell surface, facilitates 
phosphorylation of focal adhesion kinase (FAK) [76]. Activation of FAK stimulates 
the activation of Src family tyrosine kinases, which results in the activation of PI3K 
and Rho GTPases [76, 77]. Activation of PI3K and Rho GTPases following KSHV 
infection facilitates cytoskeletal rearrangements and actin polymerization [76]. 
Inhibition of PI3K reduces KSHV infectivity [76, 78, 79], suggesting that activation of 
PI3K is important for KSHV infection. The MAPK pathway is also activated upon 
receptor-ligand binding and viral entry [79]. Although activation of the MAPK 
pathway is not necessary for viral DNA entry or nuclear delivery, it does promote the 
expression of various viral latent and lytic genes, including LANA and RTA 
respectively, as well as host genes thereby promoting an intracellular environment 
that is permissive to infection [79]. 
The PI3K and MAPK signaling pathways are constitutively active in latent 
KSHV-infected PEL [80-82]. When PEL cells are treated with either a dual PI3K 
pathway inhibitor that targets the two nodes, PI3K and mTOR or with rapamycin an 
inhibitor that targets mTORC1, there is reduced PEL survival and tumor size in PEL 
xenograft tumor models [80, 81].  Inhibiting mTORC1 also inhibits tumor growth in a 
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KSHV-endothelial xenograft model in which the virus is latent [83]. These data 
suggest that the PI3K pathway is important for latent KSHV cell survival.  
Activation of the MAPK pathway is also important in facilitating KSHV 
reactivation from latency [82, 84]. Inhibition of ERK, JNK, and p38 MAPK pathways 
during TPA-mediated KSHV reactivation results in reduced expression of viral lytic 
genes and production of infectious virions [82]. Because both the PI3K and MAPK 
pathways support KSHV infection throughout its life cycle, we sought to evaluate 
inhibition of both pathways in non-Hodgkin lymphoma, which includes PEL. 
 
AMPK, A CELLULAR KINASE  
AMPK is a serine-threonine kinase composed of an alpha catalytic sub-unit and 
two regulatory units, beta and gamma [85].  AMPK is a major metabolic regulator 
that maintains energy homeostasis by responding to stress conditions that increase 
the AMP: ATP ratio such as during nutrient deprivation, oxidative stress or hypoxia 
[86, 87]. Activated AMPK leads to the activation of catabolic pathways that generate 
ATP and inhibition of anabolic pathways that consume ATP. Binding of AMP to the 
gamma subunit allosterically activates AMPK and promotes phosphorylation of 
AMPKα at Thr172 by the upstream kinase liver kinase B1 (LKB1) [88-90]. Bound 
AMP or ADP at higher concentrations prevents dephosphorylation of Thr172 [88, 
91]. AMPK can also be phosphorylated by Ca2+/calmodulin-dependent protein 
kinase kinase-β (CaMKKβ) and TAK1 [92-95]. Furthermore, AMPK may be activated 
by leptin, adiponectin, catecholamines and interleukin-6 [96-101].  
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 The role of AMPK as a tumor promoter is actively being explored [102, 103]. 
Some studies suggest that AMPK promotes tumor cell survival in vitro and in vivo. 
Inhibition of AMPK results in reduced pancreatic cell survival and apoptosis under 
normal and stressed conditions [104, 105]. AMPK also promotes survival in multiple 
myeloma, colorectal and glioma cancer cell lines [106-109]. In vivo, AMPK signaling 
is elevated in developing tumors in a glioblastoma rat model [110].  Moreover, 
mouse embryonic fibroblasts (MEFs) that are null for LBK1, a kinase that 
phosphorylates and activates AMPK, have a reduced ability to undergo oncogene-
induced transformation; and xenografts that have been prepared from AMPKα1/α2-
null MEFs exhibit reduced tumor growth in comparison to wild-type (WT) [111, 112]. 
Thus, there is accumulating evidence suggesting that AMPK promotes cancer cell 
survival by facilitating the metabolic adaptation to the tumor environment. 
CHAPTER 2. DUAL INHIBITION OF THE PI3K/MTOR AND MAPK PATHWAYS IN 
NON-HODGKIN LYMPHOMA1 
OVERVIEW 
NHL subtypes are classified based on clinical and histologic characteristics, as 
well as lymphocyte developmental stage. NHL sub-types include diffuse large B-cell 
lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Burkitt 
lymphoma (BL), primary effusion lymphoma (PEL) to name just a few.  Many 
lymphomas such as DLBCL, MCL, and AIDS-associated lymphomas are very 
aggressive and rapidly fatal if unresponsive to therapy. Indolent lymphomas, such as 
FL are also many times not curable with conventional chemotherapy. Clearly, novel 
treatment paradigms are needed to improve clinical outcomes of patients with NHL.  
INTRODUCTION 
We had previously shown that the phosphatidylinositol 3-kinase (PI3K) and 
mammalian target of rapamycin (mTOR) pathway was important for NHL survival 
and that single and dual inhibitors of this pathway effectively inhibited NHL 
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proliferation in vitro and in mouse xenograft models of NHL including FL and PEL 
[80, 113]. 
Another pathway that is linked to tumorigenesis is the mitogen activated protein 
kinase (MAPK), and many sub-types of NHL display an activated MAPK pathway 
[114-116]. 
Although conventional chemotherapeutic drugs are useful in some cases, a 
significant number of NHL patients will eventually relapse and develop resistance to 
chemotherapy, which necessitates determining additional therapeutics. Since both 
PI3K and MAPK pathways are activated in NHL, we decided to investigate 
combination therapy involving inhibition of both pathways. It has been demonstrated 
that such therapy is effective against certain solid tumors [117, 118].  
RESULTS 
In this study we used a combination of NVP-BEZ234 and AZD6244.  NVP-
BEZ235 is an imidazo[4,5-c]quinoline derivative compound, shown to inhibit PI3K 
and mTOR kinase activity both in vitro and in vivo including PEL and FL [119, 120]. 
AZD6244 is an inhibitor of MEK1 and MEK2 that does not compete with ATP 
binding. It is a potent and selective MEK1/2 inhibitor that demonstrates high activity 
in solid tumor models in vitro and in vivo [121].  
Representative types of NHL cells, including SUDHL4 (DLBCL), FL-18 (FL), 
Raji (BL), Ramos (BL), and BC-1 (PEL), were treated with 0.1 nM, 1 nM, 10 nM, 100 
nM, 1000 nM (1 µM), and 10,000 nM (10 µM) of the MEK inhibitor, AZD6244, either 
alone or in combination with 10 nM of the PI3K/mTOR inhibitor, NVP-BEZ235 for 72 
hours (Figure 2.1a). The cells were also treated with 10 nM NVP-BEZ235 alone. An 
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MTS assay was performed similar to what we previously described [80, 113]. Each 
experiment was done in triplicate and standard deviation was calculated. The 
amount of NVP-BEZ235 was kept constant at 10 nM, and increasing doses of 
AZD6244 was tested in combination with NVP-BEZ235. In each case, we observed 
that AZD6244 by itself did not have any discernable effect on cell viability in cell 
culture, even at the highest dose of 10 µM AZD6244 (Figure 2.1a). Moreover, the 
combination of different amounts of AZD6244 with 10 nM NVP-BEZ235 did not 
affect cell viability when compared to 10 nM NVP-BEZ235 alone in each case 
(Figure 2.1a). A slight decrease in cell viability was only seen at the highest dose of 
AZD6244 (10 µM) with 10 nM NVP-BEZ235.  This demonstrates that the combined 
inhibition of the PI3K and MAPK pathways was neither additive nor synergistic. 
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Figure 2.1. Simultaneous inhibition of the PI3K/mTOR and MEK/ERK pathways fails to 
synergistically reduce NHL cell proliferation in vitro. (a) Proliferation of NHL cell lines treated 
with drug(s) or vehicle were evaluated by MTS Assay using the Cell Titer 96 Aqueous One 
Solution Cell Proliferation Assay (Promega) according to the manufacturer’s instructions. 
Cells (1X105/mL) were incubated with drug(s) or vehicle for 72 hours in a 12-well plate. 
Twenty microliters of MTS reagent was added to 100µL of cell suspension in a 96-well plate 
and incubated at 37°C for 1 hour. Percent of viable cells after 72 hours treatment is shown 
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on the y-axis. The percent of viable cells for untreated cells was set as 100% for each 
sample. Elevated absorbance values are indicative of metabolically active cells.  The COLO-
205 cells (5X103 cells/100µL) were added to each well of a 96-well plate. Increasing 
concentrations of drug(s) or vehicle were added the following day. The MTS reagent was 
added after 72 hours following the addition of the drug(s) or vehicle, and incubated with the 
cells for 4 hours at 37°C. Absorbance was measured at 490nm using a FLUOstar OPTIMA 
spectrophotometer. Percent viable cells after 72 hours treatment is shown on the y-axis. The 
percent of viable cells for vehicle treated was set as 100% for each sample.  Elevated 
absorbance values are indicative of metabolically active cells. (b) Phosphorylation of ERK 
1/2 and S6 kinase were determined by Western blot of NHL cell lines treated with AZD6244 
(1µM) and/or NVP-BEZ235 (30nM) for 24 hours. Equal volume of DMSO (0.1%) was added 
for vehicle control. (c) Proliferation of cells with 25 µM CAL-101 and increasing 
concentrations of AZD6244 was determined by MTS assay after 48 hours following the 
addition of the drug(s) or vehicle as described in panel a. (d) Phosphorylation of Akt, ERK 
1/2 and S6 kinase were determined by Western blot of NHL cell lines treated with AZD6244 
(1µM) and/or CAL-101 (25µM) for 24 hours. 
 
To confirm that the drug AZD6244 used in our experiments had similar activity 
to that recorded in previous reports [122], we evaluated the effect of AZD6244 on 
the COLO-205 colorectal cancer cell line by culturing these cells in increasing 
concentrations of AZD6244 or vehicle for 72 hours.  We determined an IC50 of 
107.18 ± 2.47 nM in COLO-205 (Figure 2.1a). Similar results were seen with another 
non-small cell lung cancer cell line Calu-6, that was previously shown to be inhibited 
by AZD6244 [122] (data not shown). We also evaluated NHL cell viability in the 
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presence of increasing concentrations of the chemically unrelated MEK inhibitor, 
PD184352 [123]. We found that PD184352 was ineffective at reducing cell viability in 
various NHL cell lines except at the highest dose of 10 µM (data not shown). This 
data supports our observations made with the MEK inhibitor, AZD6244, and 
suggests that NHL cells are not addicted to the MEK/ERK pathway for survival.  
To verify that each of the drugs was inhibiting their respective targets, we 
performed Western blot analysis on the NHL cells that were treated with the above 
therapies for 24 hours (Figure 2.1b). We used phosphorylated S6K as a downstream 
marker for active PI3K/mTOR as we previously described [80, 113], and we used 
phosphorylated ERK1/2 as a downstream marker for MAPK activation [121].  We 
found that NVP-BEZ235 inhibited PI3K signaling as measured by reduced 
phosphorylated S6K levels, and that AZD6244 inhibited MAPK signaling as 
measured by reduced ERK1/2 phosphorylation (Figure 2.1b). 
To determine whether a PI3K inhibitor only would be synergistic with AZD6244, 
we evaluated the combination of 25 µM CAL-101 (a PI3Kδ inhibitor) with increasing 
doses of AZD6244 on NHL cell viability. CAL-101 (5-fluoro-3-phenyl-2-[(S)-1-(9H-
purin-6-ylamino)-propyl]-3H-quinazolin-4-one) is a small molecule inhibitor of the 
class I PI3K p110δ isoform[124]. CAL-101 has been found to have anti-tumor activity 
in patients with indolent NHL and hence we sought to investigate whether inhibiting 
PI3K p110δ and MAPK may be synergistic against NHL[125]. Figure 1c depicts a 
representative NHL cell line (Ramos) that was tested with CAL-101 and AZD6244. 
We did not observe a synergistic or additive effect when different amounts of 
AZD6244 was combined with 25 µM CAL-101 compared to 25 µM CAL-101 alone 
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(Figure 2.1c), although each drug appeared to be effective in inhibiting downstream 
effectors of the pathway. Treatment with CAL-101 inhibited phosphorylation of Akt 
and S6K, and AZD6244 inhibited phosphorylation of ERK1/2 (Figure 2.1d). We 
found similar results for FL-18 and Raji cells (data not shown). Thus, neither a dual 
inhibitor of the PI3K/mTOR pathway (NVP-BEZ235) nor a single inhibitor of PI3K 
(CAL-101) appears to synergize with AZD6244 in our system. 
We next investigated the combination of NVP-BEZ235 and AZD6244 in a 
mouse xenograft model [113]. Four-to-five-week-old athymic nude-Foxn1^nu female 
mice were injected intraperitoneally with anti-asialo GM1 antibody (Wako). The 
following day, 1x106 FL-18 lymphoma cells were subcutaneously injected with 
growth-factor reduced matrigel as we previously described [113].  Upon 
development of palpable tumors, the animals were split into four groups and treated 
by oral gavage 6 days a week with either vehicle, 45 mg/kg NVP-BEZ235, 45 mg/kg 
AZD6244, or 25mg/kg each of NVP-BEZ235 and AZD6244.   While tumors grew in 
the mice treated with vehicle, mice treated with NVP-BEZ235 showed a significant 
inhibition of tumor growth as we previously reported [121].  Interestingly, in the 
xenograft model, mice treated with AZD6244 alone did show a modest inhibition of 
tumor growth compared to vehicle treated mice. However, the combination of NVP-
BEZ235 and AZD6244 did not have a synergistic or additive effect on tumor growth 
compared to NVP-BEZ235 or AZD6244 alone (Figure 2.2a).   
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Figure 2.2. Combined inhibition of the MEK/ERK and PI3K/mTOR pathways is no more 
effective at reducing tumor burden than single blockade of the PI3K/mTOR pathway in vivo.  
(a) Athymic nude-Foxn1^nu 4-5-week-old female mice were injected subcutaneously into 
the right flank with 200 µL (1X106) of FL-18 cells. Five mice per group were treated with 
equal volume of vehicle, 45 mg/kg NVP-BEZ235, 45 mg/kg AZD6244, or 25 mg/kg each of 
NVP-BEZ235 and AZD6244 (combination therapy). Treatment involved oral gavage 6 times 
per week. Tumor volume was determined daily (L x W x D) and plotted over time. Shown for 
each time point is a box and whisker plot of the results per group. The horizontal bar 
indicates the median, the box indicates 25% and 75% of the data and the whiskers 
represent 1.5 x the interquartile range, which encompasses 50% of the data.  (b) 
Phosphorylation of ERK 1/2 or S6 protein from each treatment group was evaluated on 
paraffin-embedded tumors by immunohistochemical staining. Sections were counterstained 
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with hematoxylin, and visualized at magnifications of 200X using a Leica DMLS microscope. 
Images were acquired using the Leica DFC480 camera and associated Leica Firecam 
software. Stored TIFF images were evaluated using Adobe Photoshop CS5.1. 
 
The mice were sacrificed when maximal tumor size was reached. Tumors were 
excised, sectioned, and subjected to immunohistochemical analysis as we 
previously described [80].  S6 was consistently phosphorylated in almost all cells in 
the vehicle control group, however we found reduced phosphorylated levels of S6, a 
downstream effector of the PI3K pathway in the NVP-BEZ235 treated grafts, and 
reduced phosphorylated ERK1/2, an effector of the MAPK pathway in the AZD6244 
treated grafts (Figure 2.2b). Both markers were reduced in animals treated with both 
drugs.  This suggests that both drugs were delivered to the tumors and inhibited 
their respective targets in the tumor cells in vivo. Overall, our data demonstrate that 
the combined inhibition of the PI3K and MAPK pathways was not synergistic or 
additive in preventing tumor growth of NHL cells in vitro or in vivo.  
DISCUSSION 
Currently, there are a number of clinical trials testing MEK and PI3K or mTOR 
inhibitors in patients. Our data suggest that combining inhibitors specific for these 
two pathways may not be an effective treatment option for NHL since there was no 
preclinical evidence showing any significant enhancement of cell death in vitro or 
inhibition of tumor growth in vivo when these inhibitors were combined. This is in 
direct contrast to reports in solid tumors such as melanoma and breast cancer in 
which the combination of these inhibitors showed a synergy in curtailing tumor 
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growth in similar pre-clinical models [117, 118]. Davies et al. found that tumors with 
activating Ras mutations are more sensitive to AZD6244 than tumors with WT Ras 
[122]. Since activating mutations in Ras are infrequent in NHL [126], inhibition of the 
MEK/ERK pathway may not be as effective for NHL as for solid tumors despite the 
fact that ERK was highly phosphorylated in the cell lines tested. 
Even though MEK/ERK and PI3K/mTOR pathways are active in NHL [80, 115, 
116], our data suggests that NHL are more reliant on the PI3K/mTOR pathway than 
the MEK/ERK pathway for cell survival. Normal B-lymphocyte survival is also 
dependent on the PI3K pathway [127] and studies have shown that B-lymphocytes 
lacking BCR signaling do not survive while these cells can be rescued from 
apoptosis by being engineered to have constitutively active PI3K [127].  
Although the MEK/ERK pathway may be important in NHL pathology, we found 
that targeting this pathway alone is not sufficient to reduce NHL cell survival in vitro 
or in vivo. There are multiple arms of the MAPK pathway [66] and to see additional 
benefit in NHL, we may need to modulate a different and/or multiple arms of this 
pathway along with PI3K/mTOR inhibition to see an enhancement in the reduction of 
NHL cell viability. Based on these results, we propose that further preclinical studies 
should be performed before a combination of MEK 1/2 and PI3K inhibitors is 
evaluated in a clinical trial setting for patients with NHL.
CHAPTER 3. THE KSHV K1 PROTEIN MODULATES AMPK FUNCTION TO 
ENHANCE CELL SURVIVAL2 
OVERVIEW 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiologic agent of 
Kaposi’s sarcoma (KS) as well as two lymphoproliferative diseases, primary effusion 
lymphoma and multicentric Castleman’s disease. KSHV encodes viral proteins, such 
as K1, that alter signaling pathways involved in cell survival. Expression of K1 has 
been reported to transform rodent fibroblasts, and K1 transgenic mice develop 
multiple tumors, suggesting that K1 has an important role in KSHV pathogenesis. 
We found that cells infected with a KSHV virus containing a WT K1 gene had a 
survival advantage under conditions of nutrient deprivation compared to cells 
infected with KSHV K1 mutant viruses. 5’ adenosine monophosphate-activated 
protein kinase (AMPK) responds to nutrient deprivation by maintaining energy 
homeostasis, and AMPK signaling has been shown to promote cell survival in 
various types of cancers. Under conditions of AMPK inhibition, we also observed 
that cells infected with KSHV containing a WT K1 gene had a survival advantage 
compared to KSHV K1 mutant virus infected cells. To explore the underpinnings of 
this phenotype, we identified K1-associated cellular proteins by tandem affinity 
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purification and mass spectrometry. We found that the KSHV K1 protein associates 
with the gamma subunit of AMPK (AMPKγ1). We corroborated this finding by 
independently confirming that K1 co-immunoprecipitates with AMPKγ1. Co-
immunoprecipitations of wild-type K1 (K1WT) or K1 domain mutants and AMPKγ1, 
revealed that the K1 N-terminus is important for the association between K1 and 
AMPKγ1. We propose that the KSHV K1 protein promotes cell survival via its 
association with AMPKγ1 following exposure to stress.  
INTRODUCTION 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of the 
endothelial cancer, Kaposi’s sarcoma (KS), and two B-cell lymphomas including 
primary effusion lymphoma (PEL) and multicentric Castleman’s disease (MCD) [1-3]. 
KSHV-related malignancies primarily arise in immune-suppressed individuals 
including HIV-positive individuals and organ transplant recipients, although these 
cancers can also occur in the absence of immunosuppression. KS is a common 
cancer in some sub-Saharan African countries [4, 128].  
KSHV is a double-strand DNA gammaherpesvirus that is 165 to 170 kb long 
[129]. The KSHV genome contains multiple open reading frames that are conserved 
among other herpesviruses, and genes K1-K15 that are unique to KSHV [7]. Similar 
to other herpesviruses, KSHV has latent and lytic phases. Upon entering the host 
cell, KSHV typically establishes latency and expresses a limited number of viral 
proteins. Upon reactivation, which can be induced in vitro with various compounds 
such as 12-O-tetradecanoylphorbol-13-acetate (TPA), histone deacetylase (HDAC) 
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inhibitors, and TLR 7/8 ligands, KSHV enters the viral lytic cycle resulting in the 
production of infectious virions [7, 36].  
Both latent and lytic phases appear to be important for KSHV pathology. 
Expression of latent genes generally promotes the survival of the infected cell and 
persistence of infection during cell division. Lytic gene expression results in the 
production of inflammatory cytokines, pro-angiogenic factors and viral proteins that 
subvert the host immune system and promote virion production. KSHV K1 is 
primarily expressed during the lytic phase although recent studies indicate that K1 is 
also expressed at low levels during latency [24, 35, 45].  
K1 is a 46-kDa transmembrane glycoprotein that contains a C-terminal 
immunoreceptor tyrosine-based activation motif (ITAM) analogous to the signaling 
molecules in the B-cell receptor (BCR) signaling complex [47]. The K1 ITAM has 
been found to interact with various SH2 containing signaling molecules, including 
among others, the p85 regulatory unit of phosphoinositide-3-kinase (PI3K) [50]. K1 
has been shown to initiate a signaling cascade leading to intracellular calcium 
mobilization, upregulation of NFAT and AP-1 transcription factors, and production of 
inflammatory cytokines [47, 50]. It is thought that K1 is maintained in an activated 
state by oligomerization of the K1 ectodomain and subsequent phosphorylation of 
the ITAM tyrosines by Src family kinases [49].  
K1 has a role in KSHV-induced tumor development. K1 expression 
immortalizes primary endothelial cells, transforms rodent fibroblasts, and K1 
transgenic mice develop spindle cell sarcomatoid tumors and plasmablastic 
lymphoma, suggesting that the K1 protein is important for KSHV-induced tumor 
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development [54-56]. These cancerous phenotypes may be due to K1’s modulation 
of cellular proteins in signaling pathways that are important for cell survival. We and 
others have previously shown that K1 activates the PI3K/Akt/mTOR pathway and 
protects against Fas-mediated apoptosis [51-53].  
In our current studies, we observed that cells infected with KSHV viruses 
containing a wild-type K1 gene (KSHV-K1WT and KSHV-K1REV) displayed a survival 
advantage under conditions of nutrient deprivation compared to viruses containing 
mutant K1 genes (KSHV-K15XSTOP and KSHVΔK1). To understand the underpinnings 
of this phenotype, we performed tandem affinity purification and mass spectrometry 
to identify K1 binding proteins. We found that KSHV K1 associates with the gamma 
subunit of 5’adenosine monophosphate-activated protein kinase (AMPKγ1).  
AMPK is a heterotrimeric serine/threonine kinase composed of an alpha 
catalytic sub-unit and two regulatory subunits, beta and gamma [85]. Each subunit is 
part of a larger isoform family including the following subunit isoforms: α1, α2, β1, 
β2, γ1, γ2, and γ3 [130-133]. The isoforms of each subunit are found in different 
compartments within the cell. AMPKα1 and AMPKα2 localize to the cytoplasm. 
AMPKα2 also localizes to the nucleus in rat pancreatic and HeLa cells [134]. 
AMPKα1 and AMPKβ1 are in the perinuclear region in HEK-293 cells [135]. In 
mammalian neuron nuclei, AMPKα2, AMPKβ1, and AMPKγ1 are located in the 
nucleus [136]. The subunit isoforms can come together in various combinations to 
form different heterotrimers. The differences in function of each heterotrimer are still 
under investigation. The presence of the three subunits is necessary for full 
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activation of AMPK, and the regulatory subunits stabilize expression of the catalytic 
α subunit [137]. 
AMPK responds to stresses that reduce ATP levels by inhibiting anabolic and 
activating catabolic pathways to maintain energy homeostasis [86]. Binding of 
adenosine monophosphate (AMP) to the gamma subunit allosterically activates 
AMPK and promotes phosphorylation of AMPKα at Thr172 by upstream kinases [88-
90]. AMPK also responds to environmental stress factors that reduce cellular ATP 
levels such as hypoxia [111, 138-140]. 
The role of AMPK as a tumor promoter is actively being explored [102, 103]. 
Some studies suggest that AMPK promotes tumor cell survival in vitro and in vivo. 
Inhibition of AMPK reduces prostate cell survival and increases apoptosis under 
normal and stressed conditions [104, 105]. AMPK promotes survival in multiple 
myeloma, colorectal and glioma cancer cell lines [107-109]. In vivo, AMPK signaling 
is elevated in developing tumors in a glioblastoma rat model [110].  Moreover, 
xenografts that have been prepared from AMPKα1/α2-null MEFs exhibit reduced 
tumor growth in comparison to wild-type (WT) MEFs [111]. Thus, there is 
accumulating evidence suggesting that AMPK may promote cancer cell survival and 
tumor development. 
 Here we report that K1 binds AMPKγ1 and that this interaction is important for 
K1’s ability to enhance cell survival. 
RESULTS 
Cells infected with KSHV containing WT K1 display increased survival. 
BAC16 recombinant viruses containing WT K1 (KSHV-K1WT and KSHV-K1REV) were 
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made as previously described [141]. Immortalized human umbilical vein endothelial 
cells (HUVEC) [55] or iSLK cells were infected with BAC16 recombinant viruses 
containing WT K1 (KSHV-K1WT and KSHV-K1REV) or mutant K1 (KSHV-K15XSTOP and 
KSHVΔK1) genes [141]. These recombinant BAC16 viruses contain a GFP marker 
to monitor cell infectivity [141]. Both HUVEC and iSLK cells were stably selected 
until 100% of cells were green indicating that all cells were infected with these 
viruses.  
 Each HUVEC cell line was then subjected to stress by withdrawing serum and 
growth factors. KSHV-K1WT and KSHV-K1REV (revertant) harbor a wild type K1 gene 
while the KSHV-K15XSTOP and KSHVΔK1 lack K1 (Fig. 3.1A). We evaluated cell 
viability at various time-points by MTS ([3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt), which is a 
measurement of metabolic activity, and trypan blue exclusion assay. At 24, 48, and 
72 hours following nutrient deprivation, HUVEC infected with KSHV-K1WT and 
KSHV-K1REV had more viable cells compared to the KSHV-K15XSTOP and KSHVΔK1 
HUVEC as observed using the MTS assay (Fig. 3.1B). The differences were 
greatest at 72 hours post-nutrient deprivation.   
To further substantiate these results, we also performed trypan blue exclusion 
assays and observed that the KSHV-K1WT and KSHV-K1REV infected cells were 
more viable compared to the cells infected with KSHV-K15XSTOP and KSHVΔK1 
infected cells at 48 and 72 hours (Fig. 3.1C). Similar to the MTS assay results, we 
observed reductions in cell viability in KSHV-K15XSTOP and KSHVΔK1 infected cells 
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compared to KSHV-K1WT and KSHV-K1REV infected cells at 24, 48, and 72 hours 
post-starvation (Fig. 3.1C). 
  Furthermore, iSLK cell lines stably infected with these same viruses (KSHV-
K1WT, KSHV-K1REV, KSHV-K15XSTOP and KSHVΔK1) were also evaluated following 
serum withdrawal. Every two days for a total of 12 days, we evaluated cell viability 
by trypan blue exclusion. At all time-points following serum withdrawal, we observed 
that KSHV-KTWT and KSHV-K1REV infected iSLK cells had increased viability 
compared to KSHV-K15XSTOP and KSHVΔK1 iSLK cells (Fig. 3.1D). These findings 
suggest that K1 promotes KSHV-infected cell survival in the context of the whole 
genome and under conditions of nutrient deprivation. 
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Figure 3.1. KSHV K1 mutant infected cells exhibit decreased survival following 
nutrient deprivation. (A) KSHV-K1WT and KSHV-K1REV (revertant) harbor a wild type K1 
gene. The KSHV-K15XSTOP has a K1 mutant gene that contains 5 stop codons. Three of the 
stop codons follow the first start codon of the K1 gene. The other two stop codons replace 
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two downstream ATG codons at positions 481 and 763 in the K1 gene. The KSHVΔK1 
mutant has had the K1 gene replaced by a RpsL-Neo cassette. Hence, the KSHV-K15XSTOP 
and KSHVΔK1 are not able to express the K1 protein. The grey box represents FLAG and 
horizontal lines represent the stop codons in KSHV-K15XSTOP. HUVEC infected with KSHV-
K1WT, KSHV-K15XSTOP, KSHVΔK1 or KSHV-K1REV were starved of serum and growth factors 
for 24, 48 and 72 hours. (B) The proportion of viable cells within each group was determined 
using an MTS assay. (C) The number of viable cells/well for each group was determined by 
trypan blue exclusion assay. Error bars are the standard deviation of biological triplicates. 
(D) KSHV-K1WT, KSHV-K15XSTOP, KSHVΔK1, and KSHV-K1REV infected iSLK cells were 
cultured without serum. Cell viability was determined by trypan blue exclusion. Error bars 
are the standard deviation of biological triplicates. GraphPad Prism was used to determine 
one-way ANOVA and Tukey’s post-test. *P<0.05 ,**P<0.005  
 
A major regulator of metabolic stress is AMP-activated protein kinase (AMPK). 
AMPK responds to metabolic stress by activating catabolic pathways and inhibiting 
anabolic cell signaling pathways to maintain energy homeostasis [142]. Because we 
observed that cells infected with KSHV expressing a WT K1 gene had a survival 
advantage compared to cells infected with KSHV K1 mutant viruses following 
exposure to metabolic stress, and AMPK is involved in maintaining metabolic 
homeostasis, we hypothesized that K1 might modulate AMPK function. To explore 
this possibility, we compared cell survival in HUVEC infected with KSHV-K1WT and 
KSHV-K1REV wild-type viruses to KSHV-K15XSTOP and KSHVΔK1 mutant viruses 
following treatment with the AMPK inhibitor, compound C. Compound C is a 
reversible and competitive inhibitor of ATP [143]. In the presence of 5µM ATP and 
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absence of AMP, compound C has a Ki of 109 ± 16 nM [143]. Compound C 
significantly prevents AMPK activation in vitro at 20 µM and 40 µM in cells treated 
with the AMPK activators metformin or AICAR [143]. According to Zhou et al., 
compound C has minimal impact on structurally related kinases such as ZAPK, SYK, 
PKCθ, PKA and JAK3 [143]. Inhibition of AMPK by compound C has been shown to 
induce cell death in various cell lines [105, 144].   
We observed increased cell viability in KSHV-K1WT and KSHV-K1REV infected 
cells compared to KSHV-K15XSTOP infected cells by MTS assay (Fig. 3.2A). 
Corroborating these results, we also observed increased cell viability in KSHV-K1WT 
and KSHV-K1REV compared to KSHVΔK1 infected cells, suggesting that cells 
infected with WT K1 virus are less sensitive to the stress induced by AMPK inhibition 
than cells infected with the KSHV K1 mutants (Fig. 3.2B). As expected, cell viability 
between KSHV-K1WT and KSHV-K1REV infected cells was essentially the same (Figs. 
3.2A and 3.2B).   
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Figure 3.2. Cells infected with KSHV containing WT K1 are more resistant to AMPK 
inhibition than cells infected with KSHV K1 mutants. HUVEC infected with viruses 
containing a WT or mutant K1 gene were treated with 20 µM of compound C or vehicle 
control (DMSO = 0.2%) for 48 hours. The percent of metabolically active cells was 
determined using an MTS assay. Percentages were derived from normalization to vehicle 
treated samples.  (A) The percent of metabolically active HUVEC stably infected with the 
recombinant viruses KSHV-K1WT, KSHV-K15XSTOP, and KSHV-K1REV. (B) The percent of 
metabolically active of HUVEC stably infected with KSHV- K1WT, KSHVΔK1, and KSHV-
K1REV. Error bars represent the standard deviation of biological triplicates. GraphPad Prism 
was used to determine one-way ANOVA and Tukey’s post-test. *P<0.02, **P<0.01, 
***P<0.001.  
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To evaluate the impact of K1 expression by itself on cell survival following 
treatment with the AMPK inhibitor, compound C, we created FLAG epitope-tagged 
K1 (K1) or empty vector (EV) HEK-293 stable cell lines. The EV or K1 HEK-293 cells 
were treated with increasing concentrations of compound C, and cell viability was 
evaluated by trypan blue exclusion assay. We observed an increased number of 
viable cells in the K1 expressing cells compared to EV expressing cells using two 
different concentrations (10 µM and 20 µM) of compound C (Fig. 3.3A). We 
observed this difference at both 8 and 24 hours following incubation of the cells with 
10 µM compound C (Fig. 3.3B). In order to determine whether K1 protected from 
apoptosis induced by AMPK inhibition, we also performed an assay to detect active 
caspase-3, which is an indicator of apoptosis. Active caspase-3 levels were 
remarkably elevated in EV cells compared to K1 expressing cells, suggesting that 
K1 protects cells from apoptosis when AMPK is inhibited (Fig. 3.3C). K1 expression 
in these cells was confirmed by a Western blot (Fig. 3.3D). This data suggests that 
K1 expression can keep cells alive by diminishing the effects of AMPK inhibition. 
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Figure 3.3. K1 expression provides a survival advantage in cells treated with 
compound C. (A) HEK-293 cells stably expressing empty vector (EV) or FLAG-K1 (K1) 
were treated in duplicate with 0 µM/ DMSO (0.2%), 20 µM compound C (CC) or 10 µM 
compound C for 6-8 hours. (B) HEK-293 cells stably expressing EV or K1 were treated in 
duplicate with 0 µM/DMSO (0.1%) or 10 µM compound C (CC) for 8 and 24 hours. Cell 
viability was determined by trypan blue exclusion assay. Percentages were derived from 
normalization to vehicle treated samples. (C) The level of caspase-3 activity was determined 
and normalized to cell number. (D) EV or K1 HEK-293 cells treated with either 0 µM/DMSO 
(0.1%) or 10 µM compound C for 6 hours and immunoblotted for K1 and tubulin. Statistical 
significance was evaluated by Student’s t test. *P<0.05, **P<0.005  
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The KSHV K1 protein associates with the gamma subunit of AMPK 
(AMPKγ1). To investigate how K1 may be promoting cell survival following exposure 
to metabolic stress, we wanted to determine cellular proteins associated with K1. We 
identified K1-associated cellular proteins by performing tandem affinity purification of 
K1 from HEK-293 cells and subjecting cellular proteins bound to K1 to mass 
spectrometry.  
Stable cell lines expressing a FLAG and HA double epitope-tagged version of 
K1 and EV HEK-293 cells were generated as previously described [145]. For 
tandem affinity purification, FLAG-HA-K1 or EV HEK-293 expressing cells were 
lysed with NP40 buffer. The clarified lysates were incubated with anti-FLAG M2 
affinity gel, washed with NP40 buffer, and then eluted with 3X FLAG peptide. The 
eluates were subsequently incubated with an anti-HA resin, washed with NP40 
buffer and eluted. The eluates were resolved by sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and Coomassie stained. Only bands that were present 
in the K1 lane and absent in the EV lane were isolated and submitted for 
MALDI/TOF/TOF mass spectrometry (Fig 3.4A).  
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Figure 3.4. K1 associating proteins determined by mass spectrometry. A) Stable cell 
lines expressing a FLAG and HA double epitope-tagged version of K1 and EV HEK-293 
cells were subjected to tandem affinity purification. FLAG-HA-K1 or EV HEK-293 expressing 
 40 
cells were lysed and the lysates were incubated with anti-FLAG M2 affinity gel, washed and 
eluted with 3X FLAG peptide. The eluates were subsequently incubated with an anti-HA 
resin, washed with NP40 buffer and eluted. The eluates were resolved by sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie stained. (B) The eluates 
from (A) were also subjected to SDS-PAGE and Western blot analysis with an anti-FLAG 
antibody to detect the presence of the monomer and oligomeric forms of K1. (C and D) 
Mass spectrometry analysis identified HSP90 (C) and AMPKγ1 also known as PRKAG1 (D) 
as K1 associating proteins. The peptide sequences of Hsp90 and AMPKγ1 identified by 
mass spectrometry are shown. Asterisk indicates modified amino acids. 
 
We also confirmed successful pull-down of FLAG-HA-K1 by detecting FLAG by 
SDS-PAGE and Western blot (Fig. 3.4B). Using mass spectrometry, we found 
AMPKγ1 associated with K1 (Figs. 3.4D and 3.5A). We also observed an 
association between K1 and heat-shock protein 90 (HSP90) (Figs. 3.4C and 3.5A), 
which confirmed our previous report on the association of K1 with HSP90 [145].  
 41 
 
Figure 3.5. K1 associates with AMPKγ1.  (A) Number of PRKAG1 (AMPKγ1) and HSP90 
peptides identified in association with K1 by mass spectrometry. (B) HEK-293 cells stably 
expressing empty vector (EV) or FLAG-K1 (K1) were transfected with V5-AMPKγ1 
(AMPKγ1). AMPKγ1 was immunoprecipitated, and immunoblotted for K1 or AMPKγ1. (C) 
HEK-293 cells stably expressing EV or K1 were transfected with AMPKγ1 or EV (pcDNA3). 
K1 was immunoprecipitated and immunoblotted for AMPKγ1 or K1. 
 
Next, we constructed a V5 epitope-tagged AMPKγ1 (AMPKγ1) in pcDNA3 
vector. To confirm the association between K1 and AMPKγ1 as determined by mass 
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spectrometry, we transiently expressed AMPKγ1 in HEK-293 cells stably expressing 
EV or FLAG epitope-tagged K1 (K1). We performed a co-immunoprecipitation by 
incubating EV- or K1-expressing HEK 293 clarified lysates containing equal amounts 
of protein with anti-V5 antibody to pull down the V5 epitope-tagged AMPKγ1. We 
detected the multimer and monomer forms of K1 co-immunoprecipitating with 
AMPKγ1 in K1-expressing cells, but not from EV control cells  (Fig. 3.5B). To further 
substantiate the association between K1 and AMPKγ1, we performed the reverse 
immunoprecipitation and immunoprecipitated K1.  We observed that AMPKγ1 co-
immunoprecipitated with K1 from K1-expressing cells but not from EV control cells 
(Fig. 3.5C).  
 
In the cell, AMPKγ1 complexes with AMPKα1 and AMPKβ1.  In addition to 
AMPKγ1, we next wanted to determine whether the other AMPK subunits were part 
of the protein complex associated with K1. We transfected V5-AMPKγ1 in HEK-293 
cells stably expressing empty vector (EV) or FLAG-K1 (K1), immunoprecipitated V5-
AMPKγ1, and probed for endogenous AMPKα1 and AMPKβ1. In addition to 
detecting K1 as we previously observed, we also observed the expression of 
AMPKα1 and AMPKβ1 (Fig. 3.6A), suggesting that there is an association between 
K1 and the three subunits of AMPK. Next we wanted to determine whether we could 
detect association of K1 and endogenous AMPK. Because our antibody for AMPKγ1 
was not appropriate for immunoprecipitation, and we had detected AMPKβ1 in the 
complex with AMPKγ1 and K1; we immunoprecipitated endogenous AMPKβ1 and 
probed for K1 (Fig. 3.6B). Upon AMPKβ1 immunoprecipitation, we detected K1, 
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further confirming an association between K1 and the endogenous AMPK complex 
(Fig. 3.6B). 
 
Figure 3.6. The K1 N-terminus is important for association with AMPKγ1. (A) HEK-293 
cells stably expressing empty vector (EV) or FLAG-K1 (K1) were transfected with V5-
AMPKγ1 (AMPKγ1). AMPKγ1 was immunoprecipitated, and blots were probed for AMPKγ1, 
endogenous AMPKα1, endogenous AMPKβ1 and K1. (B) Endogenous AMPKβ1 was 
immunoprecipitated from EV or K1 expressing HEK-293 cells. The blots were probed for K1 
or AMPKβ1. (C) HEK-293 cells were transiently transfected with AMPKγ1 and with one of 
the following: K1WT, K1ΔCT or K1ΔNT. An equivalent amount of EV (pcDNA3) was also 
transfected along with K1WT. We immunoprecipitated the various K1 domain mutants, and 
immunoblotted for AMPKγ1 or K1. 
K1 has an immunoglobulin-like N-terminus, a transmembrane region, and a 
cytoplasmic tail containing an ITAM. To identify the region of K1 that associates with 
AMPKγ1, we performed co-immunoprecipitations of various FLAG-tagged K1 
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domain deletion mutants and V5-tagged AMPKγ1. We transiently expressed V5-
AMPKγ1 (AMPKγ1) along with one of the following in HEK-293 cells: K1WT, K1 
lacking the C-terminus (K1ΔCT), or lacking the N-terminus (K1ΔNT). We also 
transfected an equivalent amount of EV (pcDNA3) and K1WT as a control. The 
construction of the FLAG-tagged K1 mutants has previously been described [145]. 
We immunoprecipitated K1WT, K1ΔCT, or K1ΔNT and probed for V5-tagged AMPKγ1 
(Fig. 3.6C). As previously observed, we detected co-immunoprecipitation of AMPKγ1 
and K1WT (Fig. 3.6C, lane 1). We also detected co-immunoprecipitation of AMPKγ1 
and K1ΔCT indicating that the K1 C-terminus is not important for K1 and AMPKγ1 
association (Fig. 3.6C, lane 2). We did not observe co-immunoprecipitation of 
AMPKγ1 and K1ΔNT suggesting that AMPKγ1 associates with K1 via the K1 N-
terminus (Fig. 3.6C, lane 3).  
K1 and AMPK subunits are localized to cellular membranes. About 10-20% 
of K1 is localized to the plasma membrane with the major fraction of K1 being found 
in the endoplasmic reticulum [46]. K1 can also be internalized and internalization is 
associated with K1 signaling [146]. Additionally, all three subunits of AMPK have 
been shown to localize to the cellular membrane fraction [135]. We wanted to 
evaluate the localization of the endogenous AMPK subunits in EV- and K1-
expressing stable HEK-293 cells. We lysed equal numbers of EV- and K1-
expressing HEK-293 cells and separated the cellular fractions. The fractions were 
then resolved by SDS-PAGE and Western blot. The blots were probed using 
antibodies specific for each AMPK subunit and isoform. In addition to being localized 
to the cytoplasm, we observed that AMPKα, AMPKβ1, and AMPKγ1 were detected 
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in the cellular membrane fraction (Fig. 3.7A). Along with the AMPK subunits, K1 was 
also found in the membrane fraction (Fig. 3.7A). We evaluated the purity of the 
cytoplasmic, membrane, and nuclear fractions by probing for MEK1/2, K1, and 
histone H3 respectively (Fig. 3.7A). These proteins are restricted to each of these 
fractions. Based on these findings, we conclude that K1 and multiple AMPK subunits 
and isoforms (without over expression) are localized to the cellular membrane 
fraction, suggesting that K1 associates with AMPK in the cellular membrane.  
 
Figure 3.7. K1 and AMPK are visualized in membranes and the perinuclear area of the 
cell. (A) HEK-293 cells stably expressing empty vector (EV) or FLAG-K1 (K1) were lysed 
and fractionated into cytoplasmic, membrane and nuclear fractions. Immunoblots were 
probed for endogenous AMPK subunit and isoforms. (B) HUVEC stably expressing empty 
(EV) or FLAG-K1 (K1) were fixed and permeabilized. Cells were then stained with anti-FLAG 
directly conjugated to FITC antibody, and an AMPKβ1/2 antibody, followed by an anti-rabbit 
conjugated to Alexa Fluor 647. Nuclei were stained with DAPI. Stained HUVEC were 
evaluated with a Zeiss 700 confocal microscope using a 63X oil objective. Mander’s overlap 
coefficient for this image (R = 0.83) was generated using ImageJ.  
 46 
 
We subsequently evaluated localization of FLAG-K1 (K1) and endogenous 
AMPK by immunofluorescence staining. Because our AMPKγ1 antibody is not 
appropriate for immunofluorescence staining, and we had determined that AMPKβ1 
co-localized with K1 (Fig. 3.6B), we stained for K1 and endogenous AMPKβ1/2 in 
EV- or K1- stably expressing HUVEC. We fixed the cells with formaldehyde, washed 
and then permeabilized the cells with Triton-X-100.  We stained cells with FLAG-K1-
FITC and AMPKβ1/2 antibodies followed by an anti-rabbit Alexa Fluor 647 
secondary antibody.  By confocal microscopy, we acquired z-stacks on fully stained 
EV and FLAG-tagged K1 HUVEC (Fig. 3.7B).  We also completed z-stacks on 
controls containing only the secondary anti-rabbit AF647 in order to demonstrate 
that the staining for AMPKβ1/2 is specific and not due to non-specific secondary 
staining. We observed co-localization of K1 and endogenous AMPKβ1/2 in the 
perinuclear area (Fig. 3.7B) as determined by a Mander’s overlap coefficient of 0.83, 
which was determined using ImageJ software. The EV transfected cells stained 
positive for AMPKβ1/2 but not K1, as expected. 
In Fig. 3.6C we had observed that K1ΔNT does not associate with AMPKγ1 by 
co-immunoprecipitation. K1ΔNT, lacks the signal peptide sequence, therefore we 
wanted to confirm that its lack of association with AMPKγ1 is not due to being 
mislocalized in the cell. Thus, we transiently expressed K1ΔNT, and fractionated the 
cell lysates into cytoplasmic, membrane and nuclear components. We then 
evaluated K1ΔNT expression in the membrane fraction by immunoblotting for K1ΔNT. 
We observed that K1ΔNT is in the membrane fraction (Fig. 3.8A). We also evaluated 
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the fractionation efficiency by immunoblotting for MEK1/2, AIF, and Histone H3, 
indicators for the cytoplasm, membrane and nucleus, respectively. To corroborate 
our previous findings, we confirmed that K1WT and AMPKγ1 associate in the 
membrane fraction and that there is loss of K1ΔNT and AMPKγ1 association in the 
membrane fraction by co-immunoprecipitation. Thus, we immunoprecipitated EV 
(pcDNA3), K1WT, K1ΔCT, or K1ΔNT and probed for V5-tagged AMPKγ1. We detected 
K1WT and AMPKγ1 association, and we did not detect K1ΔNT and AMPKγ1 
association in the membrane fraction (Fig. 3.8B). 
 
Figure 3.8. K1 N-terminus is important for K1 association with AMPKγ1 in the 
membrane fraction. (A) HEK-293 cells were transfected with EV (pcDNA3), K1WT, K1ΔCT, 
and K1ΔNT, and then fractionated into cytoplasmic (cyto.), membrane (memb.) and nuclear 
(nucl.) fractions. FLAG was detected in the membrane fraction by Western blot. The 
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fractionation efficiency was evaluated by detecting AIF (membrane), MEK1/2 (cytoplasm), 
and Histone H3 (nucleus).  (B) HEK 293 cells were transfected as described in (A) with the 
addition of V5-AMPKγ1. The cells were fractionated, and FLAG was immunprecipiated using 
the membrane fraction. V5-AMPKγ1 was detected by immunoblot.  
 
K1 and AMPK association is important for cell survival following exposure 
to stress. Thus far, we have observed that KSHV K1 promotes survival in stressed 
cells, and K1 associates with AMPK via the K1 N-terminus. We next wanted to 
determine whether the association of K1 and AMPK is important for the survival 
advantage observed in stressed cells. We generated lentivirally transduced HEK-
293 cells stably expressing FLAG epitope-tagged K1WT, K1ΔCT, K1ΔNT and empty 
vector (EV). We treated these cells with the AMPK inhibitor, compound C, and 
evaluated cell viability using the MTS assay. We observed an increased percentage 
of viable K1WT expressing cells when AMPK was inhibited, compared to cells 
expressing K1ΔNT. This result suggests that the association between K1 and AMPK 
is important for survival in stressed cells (Fig. 3.9A). Surprisingly, we also observed 
that K1ΔCT expressing cells appear sensitive to AMPK inhibition, indicating that the 
K1-C terminus is also important for survival in stressed cells (Fig. 3.9A). We 
confirmed expression of the various K1 constructs by completing a Western blot 
using an anti-FLAG antibody or an anti-K1 antibody (Fig. 3.9B). When we 
immunoblotted with an anti-FLAG antibody, we observed low levels of K1ΔNT. Thus, 
we re-probed this blot using an anti-K1 antibody, and saw expression of K1ΔNT 
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expression but no K1ΔCT expression since the K1 antibody is directed towards an 
epitope on the K1 C-terminus (Fig. 3.9C). 
 
Figure 3.9. K1 and AMPK association is important for cell survival following exposure 
to stress. (A) HEK-293 cells stably expressing FLAG-tagged K1WT, K1ΔCT, K1ΔNT or empty 
vector (EV = pLenti CMV) were treated with 10 or 7.5 µM compound C for 48 hours. Cell 
viability was determined using the Promega MTS assay. The percent of metabolically active 
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cells was determined by normalization to the DMSO (0.1%) control. Error bars represent the 
standard deviation of biological triplicates. (B) Western blot showing expression of EV, K1WT, 
K1ΔCT, and K1ΔNT using an anti-FLAG antibody. (C) Western blot from (Fig. 7B) was stripped 
and probed for K1 using an anti-K1 antibody. GraphPad Prism was used to determine one-
way ANOVA and Tukey’s post-test   **P<0.005 
 
K1 facilitates AMPK activity in stressed cells. We found that K1 associates 
with AMPK and this association is important for the survival advantage in stressed 
cells. We next wanted to determine the status of AMPK activity in stressed EV and 
K1 expressing cells. We exposed HUVEC stably expressing empty vector (EV) or 
FLAG-tagged K1 (K1) to media without serum and growth factors containing either 
compound C or DMSO control for 24 hours. We then performed an AMPK-specific 
kinase activity assay. We incubated lysate from EV or K1 expressing HUVEC with or 
without an AMPK substrate, a synthetic peptide called SAMS peptide 
(HMRSAMSGLHLVKRR), AMP, and radiolabeled γ-32P-ATP [147]. We next 
evaluated the incorporation of radiolabeled phosphate from γ-32P-ATP into SAMS 
peptide. Compound C treatment resulted in an overall reduction in AMPK activity in 
both EV and K1 expressing cells compared to untreated cells. However, in the 
presence of compound C, we observed a higher degree of AMPK activity in K1 
expressing cells compared to EV expressing cells (Fig 3.10A). This data suggests 
that K1 expression promotes AMPK activity in stressed cells.  We also confirmed 
that K1 expression is not altered by nutrient deprivation and compound C treatment 
by Western blot analysis (Fig 3.10B).  
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Figure 3.10. K1-expression facilitates AMPK activity in stressed cells. (A) HUVEC 
stably expressing empty vector (EV) or FLAG-K1 (K1) were deprived of serum and growth 
factors (starve) for 24 hours. At the time of starvation, 5 µM compound C or DMSO (0.05%) 
was added. Each condition for EV and K1 was completed in triplicate. AMPK-specific activity 
was determined by subtracting counts per minute (cpm) derived for each sample incubated 
without SAMS peptide from cpm derived from each sample incubated with SAMS peptide. 
These values were then normalized to total protein for each sample. The error bars 
represent the standard deviation of triplicates. (B) Western blot of K1 and tubulin using 
lysate from the AMPK activity assay. *P<0.05 Student’s t test 
 
K1 maintains PI3K pathway despite AMPK activation. Because K1 activates 
the PI3K pathway via its ITAM in the C-terminus, we wanted to know whether the 
pathway remains active when cells are exposed to serum starvation, a condition that 
activates AMPK. Activated AMPK inhibits mTORC1 in two ways. AMPK 
phosphorylates tuberous sclerosis 2 (TSC2) and raptor; both events ultimately result 
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in the inhibition of mTORC1 [148, 149]. We either serum starved for 8 hours or 
treated HUVEC cells stably expressing EV or K1 with vehicle or oligomycin, an ATP 
synthase inhibitor and an AMPK activator. We then evaluated AMPK and S6K 
activity by completing SDS-PAGE and Western blot. With serum starvation and 
oligomycin treatment, we observed an increase in phosphorylated levels of AMPK 
compared to vehicle treated cells (Fig. 3.11). We also observed a slight increase in 
AMPK activity in K1-expressing cells compared to EV (Fig 3.11). Following serum 
starvation, there is an overall decrease in phosphorylated S6K in both EV and K1-
expressing cells compared to vehicle treated, but there is greater S6K activity with 
K1 expression than EV (Fig. 3.11). This data suggests that despite AMPK activity, 
K1 maintains PI3K pathway activation under certain conditions.  
 
 53 
Figure 3.11. K1 maintains an active PI3K pathway despite AMPK activation following 8 
hours of serum starvation. HUVEC stably expressing EV or K1 were treated with vehicle 
(DMSO), serum starved for 8 hours, or treated with 2 µM oligomyicn, an ATP synthase 
inhibitor one hour prior to cell harvest. The levels of phosphorylated and total proteins were 
determined by Western blot. 
 
DISCUSSION 
Cell survival during KSHV infection is paramount to the establishment of life-
long infection. Upon infection, KSHV primarily enters a latent state. During latency, 
KSHV expresses a limited number of proteins and microRNAs that enable it to 
successfully persist in the cell by avoiding the immune response and by promoting 
cell survival [150]. When KSHV reactivates and enters the lytic stage, the cell must 
remain viable throughout viral replication and virion assembly so that infectious 
virions are generated. Cell death prior to completion of the lytic program would result 
in defective viral replication.  
We observed that KSHV infected cells containing a WT K1 gene had a survival 
advantage compared to cells infected with KSHV K1 mutants following exposure to 
stress. To explore the underpinnings of this phenotype, we completed tandem 
affinity purification and mass spectrometry to identify K1-associating proteins. We 
identified AMPKγ1 as a K1-associating protein. We corroborated this finding 
independently and found that K1 co-immunoprecipitated with AMPKγ1. By 
performing co-immunoprecipitations of AMPKγ1 and K1 domain mutants, we found 
that the K1 N-terminus is important for K1 and AMPKγ1 association. The association 
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between K1 and AMPK is important for the survival advantage in stressed cells 
because we observed reduced cell viability in cells expressing K1ΔNT compared to 
K1WT. Our studies indicate that KSHV K1 promotes survival via its association with 
AMPK, and KSHV K1 facilitates AMPK activity in stressed cells.   
Under normal culture conditions, our lab and others have shown that K1 
activates the PI3K/Akt/mTOR pathway [50, 51]. It has been reported that cells 
having overly active Akt and consequently a high glycolytic rate are more sensitive 
to cell death following starvation compared to control cells [151]. Moreover, when 
starved-cells are treated with an activator of AMPK, cells with active Akt are 
protected from cell death [151]. KSHV-infected cells also have an active 
PI3K/Akt/mTOR pathway and a high glycolytic rate [80, 152, 153].  Furthermore, 
simultaneous activation of AMPK, Akt and mTOR, has been observed in liver cancer 
cells following nutrient starvation [154]. Thus, low levels of AMPK activation may 
promote metabolic adaptation and consequently, increase KSHV-infected cell 
survival. We propose that K1 promotes AMPK activity during metabolic stress and in 
this way enhances KSHV-infected cell survival.  
Among others, we identified another K1-associating protein, the endoplasmic 
reticulum calcium ATPase 2 (SERCA) by mass spectrometry. SERCA is a calcium 
pump that controls calcium levels by pumping Ca2+ in an ATP-dependent manner 
from the cytosol into the ER [155, 156]. Homeostatic movement of intracellular Ca2+ 
from the cytosol into the ER via SERCA and from the ER towards the mitochondria 
via inositol 1, 4, 5-triphosphate receptors (IP3Rs) is critical for the function of cellular 
processes including autophagy and apoptosis [155]. The function or expression of 
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SERCA and/or IP3Rs can be modulated by pro-tumorigenic factors such as BCL-2 
and myc, thus, promoting cell survival in a changing tumor microenvironment [155].  
AMPKα2 expression promotes SERCA activity and reduces ER stress in 
HUVEC cells [157]. Although interaction between K1, SERCA and AMPK has not 
been confirmed by co-immunoprecipitations, we speculate that K1 modulates 
SERCA activity by altering AMPK activity and consequently, alleviates ER stress. 
Increased ER stress can be detrimental to the cell and result in apoptosis [158].  
The role of AMPK during herpesvirus infection is complicated, and whether it 
promotes viral replication or inhibits it may depend on a variety of factors. During 
human cytomegalovirus (HCMV) infection, AMPK has been found to promote a 
metabolic environment that is conducive to viral replication [159, 160]. AMPK 
inhibition blocks increased glycolysis that is induced by HCMV infection and inhibits 
viral DNA synthesis [160]. Interestingly, treatment of HCMV-infected fibroblasts with 
the AMPK activator, AICAR [159, 161] or the inhibitor, compound C, results in 
reduced HCMV replication [159]. During human herpes simplex virus-1 (HSV-1) 
infection, AMPK activity facilitates neuron survival and reduces viral production 
[162]. Thus, AMPK appears to impact viral production differently during HCMV and 
HSV-1 infection.  
Recently, Cheng et al. observed that endogenous AMPKα1 inhibits KSHV 
replication following primary infection [163]. AMPK does not seem to affect KSHV 
infectivity nor trafficking to the nucleus but it does have an inhibitory affect on KSHV 
lytic gene expression since knock down of AMPK results in increased expression of 
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some KSHV lytic genes and corresponding proteins [163]. Thus, AMPK inhibits the 
KSHV lytic cycle but not the establishment of latency.  
Our studies examined the role of AMPK in latently K1 WT or mutant KSHV-
infected cells that had been subjected to stress. Our results do not contradict those 
results of Cheng et al. because we are each examining very different phases of the 
KSHV life cycle. Because AMPK can be activated by a variety of cellular stresses 
and can impact multiple cell signaling pathways, we will most likely observe that 
AMPK can differentially impact the infected-cell and the KSHV life cycle as we 
investigate further the role of AMPK during KSHV infection. Another layer of 
complexity is that there are multiple isoforms of the AMPK subunits. Therefore, 
different combinations of these isoforms can form different heterotrimeric complexes. 
We do not yet understand how the different combinations may result in altered 
functions of AMPK.   
MATERIALS AND METHODS 
Cell culture, transfections, and chemical compounds. HEK-293 (ATCC, 
CRL-1573) and iSLK cells [141] were maintained in Dulbecco’s Modified Eagle 
Medium (DMEM) and human telomerase-reverse transcriptase-immortalized human 
umbilical vein endothelial cells (hTERT-HUVEC) [55] were cultured in endothelial 
growth basal medium (EBM-2) from Lonza and supplemented with an endothelial 
cell growth medium (EGM-2) bullet kit without heparin and ascorbic acid 
supplements. All cell lines were supplemented with 10% heat-inactivated fetal 
bovine serum (HI-FBS), 1% penicillin-streptomycin (PS), and 1% L-glutamine and 
maintained at 37°C and 5% CO2. Additionally, EV (pcDNA3) or FLAG-K1 stably 
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expressing HEK-293 cells were maintained in 1 mg/mL G418. For transfection of 
HEK-293 cells, cells were transfected with 10 µg pcDNA3-V5-AMPKγ1 or vector per 
10 cm plate using XtremeGENE HP reagent according to the manufacturer’s 
instructions. The AMPK inhibitor, compound C, was purchased from Calbiochem 
and suspended in dimethyl sulfoxide (DMSO).  
Constructs. HEK-293 cells stably expressing EV or FLAG-HA-K1 were made 
as previously described [145]. Briefly, FLAG-HA was cloned following the signal 
peptide sequence on the N-terminus of K1 (Accession# AF170531). The FLAG-HA-
K1 was then cloned into the pcDNA3 vector. A V5-epitope tag was added to the N-
terminus of PRKAG1 (NP_002724) by PCR and then cloned into the pcDNA3 vector. 
The pcDNA3-K1 domain mutants were prepared as previously described [145]. The 
pcDNA3-K1 WT construct was used as a template for making the lentiviral K1 WT 
and mutant constructs. pLenti-FLAG-K1 domain mutants were generated using Q5 
Site-Directed Mutagenesis kit (Q5) by New England Biolabs Inc and appropriate 
primer sets were designed according to the Q5 kit specifications. FLAG-K1, FLAG-
K1ΔCT, and FLAG-K1ΔNT were cloned into the lentiviral vector, pLenti CMV Puro 
DEST. Empty vector is pLenti CMV Puro. DEST. pLenti-FLAG-K1 domain mutants 
were generated using Q5 Site-Directed Mutagenesis kit by New England Biolabs 
Inc. 
Generation of stable cell lines. pcDNA3-FLAG-HA-K1 or pcDNA3 empty 
vector were transfected into HEK-293 cells and selected in media containing 1 
mg/mL G418. All lentiviruses were prepared using the Virapower lentiviral 
expression system as per the manufacturer’s instructions (Invitrogen). hTERT-
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HUVEC or HEK-293 cells were cultured to approximately 80% confluency in a 6-well 
dish. At the time of lentiviral transduction, cells were rinsed with PBS and 2 mLs of 
lentivirus (unconcentrated) was added in the presence of 10 µg/mL polybrene. The 
cells were centrifuged for 90 minutes at 3000 RCF at 30°C. The cells were then 
incubated overnight at 37°C and 5% CO2. The media containing lentivirus was 
replaced with the appropriate fresh media the following day. Forty-eight hours 
following lentiviral transduction, HUVEC cells underwent selection with 0.5 µg/mL 
puromycin for 1 week. Transduced HEK-293 cells underwent selection with 1 µg/mL 
puromycin for 1-2 weeks.  
Tandem affinity purification. EV (pcDNA3) or FLAG-HA-K1 (pcDNA3) HEK-
293 cells were washed with cold phosphate buffered saline (PBS) and then lysed in 
NP40 lysis buffer containing phosphatase and protease inhibitor cocktails (Roche). 
Following lysis, clarified supernatants were subjected to tandem affinity purification 
using FLAG HA Tandem Affinity Purification Kit (Sigma). Following tandem affinity 
purification, the eluates were resolved on a 12% NPAGE Novex Bis-Tris Mini gel 
(Invitrogen). The gel was Coomassie stained and bands present in the K1 sample 
but absent in the EV were submitted to the Harvard Mass Spectrometry core for 
MALD/TOF/TOF mass spectroscopy analysis. 
Trypan blue exclusion assay. EV or FLAG-HA-K1 stably expressing HEK-293 
cells were plated at 650,000 cells/well in a 6-well dish or at 60,000/well in a 24-well 
dish. The next day, the media was removed and replaced with complete media 
containing the relevant concentration of compound C. Six to eight hours later the 
media from each well was collected; the cells were gently washed with PBS and 
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trypsinized. The cells were pelleted and resuspended in 0.6-1 mL complete media. 
An aliquot was removed for the trypan blue exclusion assay. The cells were then 
pelleted, the supernatant was discarded and the pellets were immediately frozen 
and maintained at -80°C until utilized for the caspase-3 assay. HUVEC infected with 
KSHV containing WT K1 or mutant K1 were plated at 20,000 cells per well of a 24-
well plate in EBM-2 without serum and growth factors. iSLK cells containing WT K1 
or mutant K1 were plated in a similar manner, but in complete media. The next day, 
the iSLK media was replaced with serum-free DMEM. At the time of counting, cells 
were trypsinized and cell suspension was then combined with trypan blue (0.4% 
Sigma Aldrich) at a 1:1 dilution. Each sample was counted in duplicate or triplicate 
using a hemacytometer.    
Active caspase 3 assay. The previously frozen cell pellets were thawed on ice. 
The caspase-3 assay was then completed based on the manufacturer’s instructions 
(ApoAlert Caspase-3 Fluorescent Assay by Clontech Laboratories). Briefly, the 
pellets were lysed and maintained on ice followed by centrifugation. The clarified 
supernatant was then assayed for active caspase-3 and fluorescence was 
determined using the CLARIOstar plate reader (BMG Labtech). Active caspase-3 
concentrations were determined using a standard curve, and active caspase-3 
values were then further normalized to cell number.  
MTS assay. Five thousand cells per 100 µL were counted and resuspended in 
EBM-2 containing 30 µg/mL hygromycin but lacking all other supplements. Cells 
were plated in triplicate and incubated for 24, 48 and 72 hours. Cell proliferation was 
determined using the Cell Titer 96 Aqueous One Solution Cell Proliferation Assay 
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(Promega) according to the manufacturer’s instructions. Stored aliquots of previously 
frozen MTS were thawed in a water bath at 37°C. Twenty microliters of MTS reagent 
was then dispensed into each well using a multichannel pipet. The plate was then 
gently shaken for 30 seconds and placed in an incubator at 37C° for 2-3 hours. At 
the end of incubation, the plate was gently tapped to mix the formazon product. The 
absorbance was then immediately measured at 490 nm using a CLARIOstar plate 
reader (BMG Labtech). Elevated absorbance values are indicative of metabolically 
active cells. 
Cell Fractionation. HEK-293 stably expressing EV (pcDNA3) or FLAG-HA-K1 
(pcDNA3) were washed, trypsinized, centrifuged and counted. Five million cells were 
prepared using a cell fractionation kit according to the manufacturer’s instructions 
(Cell Signaling Technology). Equal volumes of each lysate from each fraction for EV 
and K1 were loaded and resolved by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and then transferred to a nitrocellulose membrane.   
Immunoblots. Cells were harvested, washed twice with PBS, and then lysed in 
buffer containing 0.5% NP40, 150 mM NaCl, 50 mM Tris-HCL pH 8.0, and a cocktail 
of proteinase (Roche) and phosphatase (Roche) inhibitors. The lysates used to 
evaluate K1 protein expression were frozen and thawed two times. Protein 
concentrations were determined by Bradford assay. To evaluate phosphorylated 
proteins, equal amounts of protein (15-25 µg) were loaded per lane and resolved by 
SDS-PAGE and then transferred to a nitrocellulose membrane. The following 
antibodies from Cell Signaling Technology were used: phospho-AMPKα (Thr172) 
#2535, AMPKα #2603, AMPKα1 #2795, AMPKα2 #2757, AMPKβ1 #12063, 
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AMPKβ1/2 #4150, AMPKγ1#4187, phospho-p70 S6K #9204, phospho-TSC2 #5584, 
HRP-linked anti-rabbit IgG #7074 and HRP-linked anti-mouse IgG #7076. In some 
experiments K1 expression was confirmed by immunoblotting with an HRP-
conjugated mouse monoclonal anti-FLAG M2 antibody from Sigma #F1804. In other 
experiments, K1 expression was confirmed by immunobloting with an in-house 
monoclonal K1 antibody, followed by incubation with an HRP-conjugated anti-mouse 
antibody. The K1 monoclonal antibody was made by Abmart Inc., Shanghai, China 
(www.ab-mart.com). The epitope used to make this antibody is KQRDSNKTVP, 
protein ID#AAB71616 and gene accession #U86667.  
Co-immunoprecipitations. Lysates containing equal amounts of protein as 
determined by the Bradford assay were combined with EZview Red anti-FLAG M2 
affinity gel (Sigma, F2426) as per the manufacturer’s instructions. For V5-AMPKγ1 
immunoprecipitation, protein A/G agarose (Santa Cruz, sc-2003) was combined with 
monoclonal anti-V5 antibody (Sigma, V8012), which was used at 1ug of antibody/1 
mg of protein, and rotated overnight at 4°C. The next day, the supernatant was 
removed and the affinity gel or agarose pellets were washed 4X, each with 1mL of 
0.1% NP40 lysis buffer. For immunoprecipitation using the membrane fraction, 
affinity gel pellets were washed with 1mL of 0.1% NP40 lysis buffer, followed by 5 
minutes rotation at 4°C for 3 times and with 1mL 0.5% NP40 lysis buffer followed by 
5 minutes rotation at 4°C for one time. Detergent was then removed from the 
membrane fraction using Pierce Detergent spin columns. FLAG-HA-K1 and/or 
FLAG-K1 domain deleted mutants was eluted using 3X FLAG peptide (Sigma, 
F4799) as per the manufacturer’s instructions. Laemmli buffer (2X) was added to the 
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FLAG-HA-K1 eluate or directly to the V5-AMPKγ1/agarose samples (1:1) and all 
samples were heated at 100°C for 6 minutes. Proteins were resolved by SDS-PAGE 
followed by Western blot.  
AMPK activity assay. HUVEC stably expressing EV or FLAG-K1 were 
incubated in EBM-2 without serum and growth factors for 24 hours. Either 5 uM 
compound C or DMSO (0.05%) control was added at the start of starvation. Cells 
were washed with cold PBS and then lysed with a buffer containing 50mM Tris-HCL 
pH 7.4, 1 mM EDTA, 1 mM EGTA, 250 mM mannitol, 1% Triton X-100 and 
proteinase (Roche) and phosphatase inhibitors (Roche). Lysates were then clarified 
by centrifugation. For the AMPK activity assay, reagents were purchased from 
SignalChem and the manufacturer’s protocol followed. Briefly, 10 µLs of cell lysate 
was incubated with 5 µL of 1 mg/mL SAMS or peptide substrate solution, 5 µLs 0.5 
mM AMP solution and 5 µLs γ-32P-ATP assay cocktail. Gamma-32P-ATP was 
purchased from Perkin Elmer. The mixture was incubated at room temperature for 
30 minutes and then 20 µLs was added to phosphocellulose paper and washed 2 
times in 1% phosphoric acid solution.  Counts per minute (cpm) were acquired using 
a PerkinElmer liquid scintillation analyzer. 
Immunofluorescence and confocal microscopy. Approximately 120,000 
HUVEC cells stably expressing EV or FLAG-K1 were plated in MatTek 35 mm glass-
bottom dishes. Cells were washed with PBS and fixed by 15-minute incubation in 
3.7% formaldehyde at room temperature. Cells were washed 3X with PBS and then 
permeabilized by 15-minute incubation at room temperature in 0.2% Triton-X 
100/PBS. Cells were then washed again 3X with PBS and then blocked in 10% 
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bovine serum albumin (BSA) PBS for 30 minutes. Cells were stained 1:200 with a 
directly conjugated FITC-ECS (DDDDK) polyclonal antibody (Bethyl laboratories) 
and anti-AMPKβ1/2 (1:50, Cell Signaling) in 10% BSA for 1 hour at room 
temperature. Cells were washed 2X quick followed by 3X 5-minute washes. 
Samples were then incubated with anti-rabbit Alexa Fluor 647 (1:600) secondary 
antibody in 10% BSA at room temperature for 1 hour. All samples were then stained 
with DAPI for 1 minute and washed. Fluorescent images were acquired by taking z-
stacks using a 63X oil objective on a Zeiss 700 confocal microscope. The overlap 
coefficient according to Manders (R) was determined using ImageJ. 
Generation of WT or mutant K1 recombinant viruses. The construction of 
the KSHV WT and mutant recombinant viruses has previously been describied in 
detail [141]. Briefly, the BAC 16 was kindly provided by Dr. Jae U. Jung. pcDNA3 
WT and mutant K1 constructs were used as templates for construction of 
recombinant viruses. pcDNA3 WT K1 FLAG, which has a FLAG tag at the N-
terminus, was constructed as previously described [164]. The pcDNA3-K15XSTOP 
construct has 3 stop codons following the start codon of WT K1FLAG and two TGA 
stop codons replacing ATG start codons at positions 481 and 763. K15XSTOP was 
inserted into BamHI and EcoRI sites of pcDNA3-FLAG K1WT. The original K1 gene 
is located within the BAC16 genome at position 105 to 959. The recombinant viruses 
containing KSHV-K1WT, KSHV-K15XSTOP, KSHVΔK1 and KHSV-K1REV were made 
utilizing the Red/ET recombination system (Gene Bridges Inc) as per the 
manufacturer’s instructions. KSHVΔK1 was constructed by replacing the K1 gene 
with the linear RpsL-neo cassette that is flanked by homologous arms [141]. 
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Establishment of cells stably infected with WT or mutant K1 recombinant 
viruses. Five × 105 cells of WT or recombinant virus infected iSLK cells were plated 
in one well of a 6- well plate overnight after which cells were reactivated with 3 µg/ml 
doxycycline and 1 mM sodium butyrate for 3 days. Supernatant was collected and 
cleared by centrifugation at 950g for 10 min and filtered through a 0.45 µm filter. 
iSLK cells were infected as previously described [141] and maintained in the 
presence of 1 µg/ml puromycin, 250 µg/mL G418, and 1.2 mg/mL hygromycin [141]. 
In order to infect HUVEC, the filtered viral supernatants from reactivated iSLK cells 
were incubated with the immortalized HUVEC cells in the presence of 8 µg/ml of 
polybrene and centrifuged for 2 hours at 3000 RCF at 30°C. The cells were then 
placed in an incubator with 5% CO2 at 37°C.  At 48 hours post-infection, 30 µg/ml 
hygromycin was added to the media to select for HUVEC stably infected with KSHV-
K1WT, KSHV-K15XSTOP, KSHV∆K1 or KSHV-K1REV (revertant) recombinant viruses.   
The infected HUVEC cells were also maintained in the presence of 30 µg/ml 
hygromycin.  
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CHAPTER 4. THE KSHV ORF36 PROTEIN KINASE AUGMENTS 
TUMORIGENESIS IN A MOUSE MODEL SYSTEM3 
OVERVIEW 
We generated a novel vPK transgenic mouse by cloning human vPK into a 
vector under the control of the ubiquitin promoter. vPK transgenic mice were made 
and mice were screened for vPK expression. We were able to detect vPK protein in 
liver, spleen, kidney, heart, lung, thymus and lymph node of transgenic mice.  
We initially compared the splenic lymphocyte subsets in vPK transgenic mice to 
those of wild-type (WT) mice by flow cytometry. We observed increased 
percentages of CD4+ T cells, increased activated T and B cells, and increased 
germinal center B cells in spleens from vPK transgenic mice compared to WT mice. 
This suggests that vPK can activate signal transduction pathways in B and T cells. 
Furthermore, when we immunized vPK and WT mice with antigen and evaluated 
splenic lymphocyte activation by flow cytometry, we found that antigen 
administration in vPK mice did not result in additional lymphocyte activation 
compared to vehicle vPK controls, since the vPK mice already display a high level of 
lymphocyte activation. Our results suggest that naïve vPK mice have a higher 
baseline level of B and T cell activation without any prior immunization. We plan to 
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compare the proliferative response of B cells from vPK and WT mice following 
exposure to various stimulants ex vivo.    
Inflammation has been found to play an integral part in the development and 
progression of Kaposi’s sarcoma (KS). In the early stages of KS, there is an influx of 
CD8+ and CD4+ T cells along with the production of inflammatory cytokines. 
Inflammatory cytokines reactivate KSHV from latency and stimulate endothelial cells 
to produce angiogenic factors thereby promoting KS progression. Activation of cell 
signaling pathways such as PI3K/mTOR/S6K is also important for the development 
of B cell lymphomas. Hence, vPK’s ability to enhance B cell activation may also 
contribute to lymphomagenesis.   
INTRODUCTION 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is a double-strand DNA 
herpesvirus that is associated with the endothelial cell cancer, Kaposi’s Sarcoma 
(KS) and two B cell lymphomas including PEL and MCD. These KSHV-associated 
diseases mainly occur in immune-suppressed individuals such as those who are HIV 
positive or are transplant recipients.   
Unlike K1, which is unique to KSHV, vPK, also known as ORF36, is a viral 
serine/threonine kinase that is conserved among herpesviruses, underscoring the 
importance of this kinase in herpesvirus infection and KSHV biology. Although vPK 
is conserved, there are still significant differences in cellular localization and function 
of these viral kinases among different herpesviruses. Herpesvirus orthologs to KSHV 
ORF36 include UL13 (HSV-1, -2), ORF47 (VZV), UL97 (HCMV), U69 (HHV-6, -7), 
and BGLF4 (EBV) [58].  
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Viral protein kinase undergoes autophosphorylation, which is important for its 
catalytic activity, is localized to the nucleus, and is presumed to be a tegument 
protein [59, 60, 165]. When vPK is expressed ectopically, it localizes to the nucleus 
and cytoplasm [57]. Viral PK has been shown to have a multitude of functions in 
vitro. Viral PK expression results in the phosphorylation of MKK4 and MKK7 and 
subsequent phosphorylation of c-Jun N-terminal kinase (JNK) [59]. In human and 
mouse cell lines, vPK inhibits the activation of the IFNβ promoter and the production 
of IFNβ [61]. Moreover vPK has cyclin-dependent kinase like function by inducing 
the phosphorylation of Rb and lamin A thereby promoting cell cycle progression [57]. 
Our lab has recently shown that vPK resembles and mimics the activity of the 
cellular protein S6 kinase (S6KB1) [62]. S6KB1 is downstream in the PI3K/mTOR 
pathway and is phosphorylated by mTOR. Activated S6KB1 phosphorylates multiple 
targets some of which are involved in protein synthesis such as ribosomal S6 
protein, a protein that is part of the 40S ribosome; and eIF4B, a protein that is part of 
the translation pre-initiation complex [63]. Expression of vPK results in increased de 
novo protein synthesis, tubule formation, and anchorage independent growth, 
compared to empty vector suggesting that vPK may be an oncogenic protein [62].  
Until most recently, our understanding of vPK function was based on data 
obtained from in vitro systems. We wanted to determine whether vPK-expressed in 
vivo would reveal either a novel function for vPK and/or support in vitro observations; 
therefore, we generated two lines of vPK transgenic mice along with C57BL/6 
littermate controls.  
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RESULTS 
A vPK gene was inserted downstream of the ubiquitin promoter (Ub) in the 
vector, pBS.Ub.hGH (Fig. 4.1A). The transgene fragment was microinjected into 
fertilized embryos of C57BL/6 mice and subsequently implanted into 
pesudopregnant females. We screened the pups for vPK transgene expression by 
isolating mouse genomic DNA and polymerase chain reaction (PCR)(Fig. 4.1B). We 
next detected vPK protein expression in spleens from vPK and littermate WT 
controls (Fig. 4.1C). Because vPK expression is under an ubiquitin promoter and 
should be expressed in all tissues, we wanted to determine whether vPK is 
expressed throughout the body. We found vPK protein expression in multiple organs 
including liver, spleen, kidney, heart, lung, thymus and lymph nodes but not in WT 
littermate control organs (Fig. 4.1D). 
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Figure 4.1. Development of a vPK transgenic mouse model system. (A) Schematic of 
the transgene fragment used to make the vPK transgenic, which includes an ubiquitin 
promoter, the FLAG-tagged vPK/ORF36 sequence, and a stabilization sequence (hGH 
enhancer). (B) Viral PK expression in mouse genomic DNA obtained from 2 transgenic lines 
and littermate WT controls. (C) Viral PK protein expression in spleens from 2 vPK transgenic 
lines and littermate WT controls. (D) Viral PK protein expression in multiple organs from a 
vPK transgenic mouse (Line 1) and WT littermate control. LN indicates lymph node. 
 
Characterization of immune cell subsets in vPK transgenic mice. Because 
this is the first expression of KSHV vPK in vivo, we began characterizing the immune 
cell subsets in the spleens from the two lines of vPK transgenic mice and WT 
littermate controls by flow cytometry. Because KSHV infects B cells and causes B 
cell lymphomas in humans, we are particularly interested in the B cell compartment 
within the spleens of vPK transgenic mice.  
We evaluated T and B cells subsets in the spleens from vPK (lines 1 and 2) 
transgenic and WT mice by flow cytometry. Interestingly, we observed an increase in 
CD19+IgD-IgM- percentages in both vPK lines compared to WT littermates (first 
highlighted row in Table 4.1).  
When activated, naïve B cells undergo class switch recombination (CSR), also 
called isotype switching, in which the heavy chain DNA is recombined from IgM and 
IgD to IgG, IgA or IgE [166]. Following CSR, B cells lose expression of IgM and IgD. 
Thus, a subset of B cells that is negative for these markers may be class switched B 
cells [167].  
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Table 4.1: Immune cell subsets in spleens from WT and vPK transgenic mice. 
 
 
We also noted an increase in the percentages of CD4+ T cells and reduced 
percentages of CD8+ T cells in both lines compared to WT littermate controls (Table 
4.1).  
We next evaluated immune subsets in spleens from additional vPK line 2 
transgenic mice and also adjusted the flow cytometry panel to include germinal 
center B cells, which is a subset of class switched B cells. Supporting our previous 
findings (Table 4.1), we observed increased percentages of class switched B cells 
(B220+IgM-IgD-) (Table 4.2). Although not significant, there was an increase in 
germinal center B cells as indicated by B220+CD95+GL-7+ cells in the spleens from 
vPK transgenic mice compared to WT controls (Table 4.2). We also observed an 
increased T helper to cytotoxic T cell ratio (Table 4.2), which was also previously 
observed (Table 4.1). 
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Table 4.2: Immune cell subsets in spleens from WT and vPK (line 2) transgenic mice. 
 
 
Viral PK (line 2) mice had an increase in germinal center B cells. We 
corroborated this finding by evaluating the percentage of germinal center B cells in 
vPK (line 1) transgenic mice (Table 4.3).  
Table 4.3: Immune cell subsets in spleens form WT and vPK (line 1) transgenic mice. 
 
 
Based on this initial characterization of splenic immune cell subsets, which 
suggests that naïve vPK transgenics have a mildly activated immune system, we 
wanted to determine whether we could exacerbate this response in vivo by 
 72 
immunization with an antigen that induces a T-cell dependent response thereby 
generating a germinal center reaction [168].  
T-dependent antigen response in vPK transgenic mice. To determine the 
primary immune response, we immunized 8-12 week old vPK transgenics (line 1) or 
WT littermate controls intrarperintoneally with NP (4-Hydroxy-3-nitrophenylacetyl 
hapten) that is conjugated to KLH (keyhole limpet hemocyanin) or PBS without 
adjuvant (Fig. 4.1). Since previous reports indicate the presence of a germinal center 
reaction as indicated by an increase in germinal center B cells occurs at around 10 
days post immunization [37, 168], we sacrificed mice at 10 days following 
immunization.   
 
Figure 4.2. Immunization protocol for vPK transgenic and WT mice with NP-KLH or 
PBS 
We did not observe differences in total body weight indicating that NP-KLH 
immunization did not impact general health in either group (Fig. 4.3A). Because NP-
KLH immunization induces a primary immune response and this response may be 
exasperated in the vPK transgenics, there may be an influx of immune cells, 
resulting in spleens with greater mass than in immunized WT. We did not observe 
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differences in the weights of spleens between vPK and WT immunized or vehicle 
treated groups (Fig. 4.3B), suggesting that either there are no differences in the 
number of immune cells or the differences are more subtle than those observed by 
spleen weights alone. 
 
Figure 4.3. Body and spleen weights for NP-KLH immunized vPK transgenic and WT 
mice. Heterozygous vPK transgenic mice and littermate controls were immunized with NP-
KLH and alum or PBS alone and harvested 10 days post immunization. (A) Body weights for 
all mice 10 days post immunization. (B) Spleen weights for all mice at 10 days following 
immunization. 
 
The immune response in control vPK transgenic mice resembled the 
immune response in NP-KLH immunized WT mice. Next, we completed a basic 
evaluation of B cell subsets from the spleens of NP-KLH or PBS immunized vPK 
transgenics and WT mice. By flow cytometry we evaluated immature B cells, mature 
B cells, germinal center B cells and the activation status of B cell subsets. Our gating 
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strategy involved making an initial forward side scatter gate, a live cell gate, followed 
by a gate on B cells (B220) and subsequent gates to identify each subset as well as 
activation status (Fig. 4.4). 
 
Figure 4.4. Gating strategy to identify B cell subsets. Flow cytometry was completed on 
spleens from NP-KLH or PBS immunized vPK transgenics and WT controls. Gates were 
drawn to exclude dead cells and then on B220+ cells to identify B cells. Immature B cells 
were determined as being B220+IgM+IgD-, mature B cells as B220+IgM+IgD+, class 
switched B cells as B220+IgM-IgD-, and germinal center B cells as B220+CD95+GL-7+.  
 
Interestingly, we did not observe differences in the number of B cells and B cell 
subsets between vPK transgenics that had been immunized with NP-KLH compared 
to vPK controls that had received PBS (Fig 4.5 A, B, C, and D). The spleens from 
control vPK transgenics had comparable numbers of the various B cell subsets 
including total B cells (Fig. 4.5A), mature (Fig.4.5B) and immature (Fig. 4.5C) to the 
numbers from spleens of NP-KLH immunized WT mice. As we had observed in 
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previous experiments (Tables 4.1, 4.2 and 4.3), there were increased numbers of 
B220+IgM-IgD- cells or class switched B cells regardless of immunization status in 
vPK mice (Fig. 4.5D).   
 
Figure 4.5. The percentages of B cells in spleens from vPK mice immunized with PBS 
were comparable to WT immunized with NP-KLH. Flow cytometry was completed on 
cells obtained from vPK transgenic or WT mice immunized with NP-KLH or PBS. (A) The 
percentages of B220+ cells. (B) The percentages of B220+IgM+IgD+ cells. (C) The 
percentages of B220+IgM+IgD- cells. (D) The percentages of B220+IgM-IgD- cells. The 
whiskers represent the minimum and maximum values, and the horizontal line on each box 
is the median. Mock = PBS. 
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To evaluate the activation status of the various B cell subsets, we stained for 
CD69, an early activation marker found on both T and B cells, and CD86. CD86 is 
upregulated on activated B cells and is the ligand for CD28 and CTLA-4 on T cells. 
The percentages of activated, as indicated by CD69 expression, on mature and 
immature B cells were overall low in all groups but similar between WT / NP-KLH, 
vPK / NP-KLH and vPK / PBS (Fig. 4.6A and B).  
 
Figure 4.6. Activation status of B cell subsets from the spleens of immunized vPK 
transgenic and WT mice.  (A) Percentages of B220+IgM+IgD+CD69+ cells. (B) 
Percentages of B220+IgM+IgD-CD69+ cells (C) Percentages of B220+IgM-IgD-CD69+ cells 
(D) Percentages of B220+IgM+IgD+CD86+ cells (E) Percentages of B220+IgM+IgD-CD86+ 
cells (F) Percentages of B220+IgM-IgD-CD86+ cells. The whiskers are the minimum and 
maximum, and the horizontal line on each box is the median. Mock = PBS. 
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Because we are inducing a primary immune response to NP-KLH, only a small 
subset of B cells should be responsive, thus the percentages of activated B cells 
should be fairly low. Overall, the percentages of class switched CD69+ B cells were 
reduced in both vPK treated groups compared to WT groups (Fig 4.6C). We 
observed an increase in the number of activated mature, immature, and class 
switched B cells expressing CD86 in vPK / PBS treated mice, and these numbers 
were similar to the numbers obtained from splenic NP-KLH immunized WT mice (Fig 
4.6 D, E, and F), which further corroborates the idea that naïve vPK mice have an 
immune response to NP-KLH that is similar to NP-KLH-immunized WT mice. 
As observed previously (Tables 4.2 and 4.3), we also noted increased numbers 
of germinal center B cells in the vPK transgenics regardless of treatment compared 
to WT / PBS (Fig. 4.7).  
  
 
Figure 4.7. vPK transgenic mice have increased percentages of germinal center B 
cells. The percentages of germinal center B cells in spleens from vPK and WT mice 
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immunized with NP-KLH or PBS (mock) were determined using flow cytometry. Whiskers 
are the minimum and maximums. 
We also evaluated the percentages of overall T cells, T helper cells, and 
cytotoxic T cells. There were no differences between vPK / NP-KLH and vPK / PBS 
(Fig. 4.8 A, B and C). As observed previously (Tables 4.1, 4.2 and 4.3), both vPK 
treated groups had increased CD3+CD4+ T cells and reduced CD3+CD8+ T cells 
compared to WT treated groups (Fig. 4.8 B and C). 
 
Figure 4.8. Splenic T cell subsets in immunized vPK and WT mice. Viral PK and WT 
mice were immunized with NP-KLH or PBS. The percentages of T cells and T cell subsets 
were determined by flow cytometry. (A) CD3+ cells (B) CD3+CD4+ (C) CD3+CD8+. 
Whiskers are the minimum and maximums. Mock = PBS.  
 
Thus far, our data indicate that spleens from vPK mice have increased numbers 
of splenic class switched B cells, germinal center B cells and an increased CD4+ 
T:CD8+ T cell ratio compared to WT. Therefore, we were very interested to evaluate 
the activation status of these cells. We stained splenic cells with an antibody cocktail 
to identify T cells, T cell subsets, and activation status using the marker CD44, which 
is involved in adhesion and is up regulated on T cells upon activation [169]. Our 
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results using the other activation markers CD25 and CD69 were inconclusive. Viral 
PK transgenic mice immunized with either NP-KLH or PBS had increased 
percentages of activated T helper cells (CD3+CD4+CD44+) compared to WT groups 
(Fig. 4.9). There were no differences in activated cytotoxic T cells between groups 
(data not shown). 
 
Figure 4.9. vPK spleens have increased percentages of CD44 positive T helper cells 
compared to WT.  Viral PK transgenics and WT mice were immunized with either NP-KLH 
or PBS. The percentages of CD3+CD4+CD44+ cells were determined by flow cytometry. 
Mock = PBS.  
 
We also evaluated splenic T cells and T cell subsets from immunized vPK and 
WT for differences in CD86 expression. CD86, as previously noted is the ligand for 
CD28 and CTLA-4. We observed that vPK transgenics, both mock and those 
immunized with NP-KLH or PBS, had increased numbers of CD86+ T helper (Fig. 
4.10A) and cytotoxic T cells (Fig. 4.10B) compared to WT groups.  
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Figure 4.10. CD86 expression is increased on vPK T helper and cytotoxic T cells. Viral 
PK and WT mice were immunized with NP-KLH or PBS. CD86 expression was evaluated on 
CD3+ splenic T cells by flow cytometry. (A) Percentages of CD3+CD4+CD86 cells (B) 
Percentages of CD3+CD8+CD86+ cells. Whiskers are the minimum and maximum. Mock = 
PBS. 
 
CD86 is predominantly expressed on antigen presenting cells (APCs). APCs 
modulate T cell responses via CD86 ligation of CD28 or CTLA-4 on T cells. 
Interestingly, there are several reports indicating that CD86 is expressed on 
activated effector memory human T cells [170, 171]. These CD86 expressing T cells 
express major histocompatibility complex class II (MHC-II), have the ability to 
present antigen [172], and to stimulate resting or naive T cells to proliferate and 
produce interferon gamma (IFN-γ) [171, 173]. MHC-II and functional CD86 are also 
expressed on activated mouse T cells [174, 175]. Interleukin-2 (IL-2) induces the 
upregulation of CD86 expression on CD4+ and CD8+ T cells and this upregulation of 
CD86 is partially dependent on mTORC1 signaling since treatment with rapamycin 
reduces CD86 expression on T cells [170]. CD86 has also been found to be 
upregulated on T cells in various contexts of disease such as on T cells from HIV+ 
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individuals [176], on allergen specific T cells [177], on tumor infiltrating lymphocytes 
[178] and on T cells from individuals with liver disease [172].   
Aged vPK expressing mice are prone to tumor development. Because we 
observe increased numbers of class switched and germinal center B cells in vivo 
and vPK expression facilitates cellular transformation in vitro [62], we hypothesized 
that vPK mice may be more prone to tumor development than WT mice. 
Interestingly, most primary effusion lymphomas (PEL), which harbor latent KSHV, 
appear to be derived from post-germinal center B cells. 
Using a cohort of vPK and age-matched WT mice, we followed these mice for 
18-24 months after birth. When we sacrificed vPK transgenic and aged-match WT 
mice, we collected blood to obtain serum, ear biopsy to re-confirm genotype and the 
following organs: lung, liver, spleen, and kidney, as well as any observed masses or 
ascites.  
Our preliminary data suggests that aged vPK mice are more prone to tumor 
development than WT mice because we observed that a greater proportion of vPK 
mice developed tumors compared to WT mice (Fig. 4.11A).  
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Figure 4.11. Aged-vPK transgenic mice are more prone to developing tumors than WT 
mice.  (A) The total number of aged-WT and vPK transgenic mice sacrificed over time, the 
number of mice with observed masses, and the percentage of mice with masses for each 
group. (B) vPK transgenic mouse with 2 masses: one mass is located on the left side of the 
heart (arrow), and the other mass is on the lower right of the mouse’s abdomen (arrow 
head). (C) Mass extracted from vPK transgenic mouse. (D) Hematoxylin and eosin (H&E) 
staining of a tumor section from a vPK transgenic mouse. (E) Spleens from WT and vPK 
transgenic mice. (F) H&E staining of spleens from WT and vPK mice (40X).  
 
The tumors in vPK transgenic mice could be found located throughout the body 
(Fig. 4.11B) and most were large and pale (Fig. 4.11C). Hematoxylin and eosin 
(H&E) staining of tumor sections revealed a homogenous tissue composed of 
lymphocytes (Fig. 4.11D). Tumor-bearing vPK transgenic mice often had larger 
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spleens compared to WT spleens, suggesting robust lymphoproliferation (Fig. 
4.11E). By H&E staining, the spleens from tumor-bearing vPK transgenic mice had 
distorted splenic architecture compared to WT (Fig. 4.11F).  
Following an initial review of some of the H&E stained lungs, liver, kidney, 
spleen and tumor sections by blinded pathologists, about 60% of the vPK transgenic 
mice had overt lymphomas (lymph) compared to WT mice (Table 4.4). Both vPK  
lines 1 and 2 developed lymphomas. 
Table 4.4 : Viral PK transgenic mice have increased incidence of lymphoma. 
 
Overt lymphoma was determined as an effacement of normal tissue 
architecture by atypical cells. Atypical cells have features of enlarged nuclear size, 
irregular contours, prominent nucleoli and increased mitotic figures. Some WT and 
vPK transgenic mice also had lymphoproliferation (LP) (Table 4.4). 
DISCUSSION 
Our preliminary findings suggest that naïve vPK transgenic mice have an 
activated immune system that is comparable to NP-KLH-immunized WT mice, at 
least as indicated by our evaluation of splenic B and T cell subsets and activation 
status by flow cytometry. After aging, vPK transgenic mice develop tumors that 
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appear to be filled with lymphocytes. We are currently completing experiments to 
identify the tumor cells by flow cytometry and immunohistochemical staining.  Based 
on the preliminary evaluation by pathologists who have blindly evaluated H&E 
stained tissues from WT and vPK mice, the masses appear to be lymphomas. To 
determine the subtype of lymphoma, we will evaluate the vPK and WT tissues by 
immunohistochemical and flow cytometry staining using a comprehensive panel of 
markers.  
During development and in response to antigen and the cytokine milieu, B cells 
undergo several genetic rearrangements that diversify the B cell receptor and fine-
tune it for antigen recognition. It is during these processes that mutations can be 
introduced and contribute to lymphomagenesis. Such alterations are prevalent in B-
cell non-Hodgkin lymphomas [179]. We observed that vPK expression in mice 
promotes low-grade immune system activation, and we see increased numbers of 
class switched B cells and germinal center B cells, which indicate an active B cell 
response. We may speculate that vPK-induced B cell activation promotes the 
various genetic rearrangements of the BCR, and facilitates the acquisition of 
mutations that contribute to lymphomagenesis.   
Viral PK has been reported to be an S6KB1 mimic, and it phosphorylates S6 
protein. Although vPK does not phosphorylate all of the S6K substrates involved in 
translation such as eIF4B (S422), it appears to phosphorylate other substrates not 
activated by S6KB1 such as eIF4E (S209) [62]. Phosphorylation of eIF4E (S209) is 
strongly associated with cancer by its involvement in cell survival, proliferation and 
anchorage independence [180].  
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The cytokines interleukin-6 (IL-6) and interleukin-10 (IL-10) are survival factors 
for KSHV PEL, and PEL cells produce high levels of IL-6 and IL-10. [81, 181]. The 
production of IL-6 and IL-10 is dependent on translation since treatment of PEL cells 
with rapamycin, an mTORC1 inhibitor, results in eIF4E/eIF4B complex formation, 
inhibition of translation, and a reduction in the levels of IL-6 and IL-10 [81]. We may 
speculate that the phosphorylation of ribosomal protein S6 and eIF4E by vPK 
promotes translation and the production of IL-6 and IL-10. These cytokines may then 
promote the survival of pathogenic B cells leading to lymphoma. Since vPK is 
expressed ubiquitously, we may expect that vPK promotes the development of 
lymphomas by multiple contributory mechanisms.  
MATERIALS AND METHODS 
Transgenic Mice. The sequence for KSHV ORF 36 was optimized for 
translation and expression by GenScript. The optimized sequence containing the 
FLAG sequence at the N-terminus [62] was then cloned into the backbone 
pBS.Ub.hGH, a plasmid previously modified from pBluescript to include an ubiquitin 
promoter (Ub) and a stabilization sequence (hGH). The plasmid was linearized with 
restriction enzymes PvuI-HF (high fidelity) and SapI from New England BioLabs. The 
transgene fragment was microinjected into fertilized embryos of C57BL/6 mice and 
subsequently implanted into pseudopregnant female mice by UNC Animal Models 
Core Facility at the University of North Carolina at Chapel Hill. Viral protein kinase-
expressing mice were identified by isolating mouse genomic DNA from foot or tail 
biopsies and by completing polymerase chain reaction (PCR). The Institutional 
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Animal Care and Use Committees at The University of North Carolina at Chapel Hill 
approved all experiments.  
Genotyping and PCR. To evaluate vPK expression in mouse foot, tail, or ear 
biopsies, each tissue sample was resuspended in 0.1mL of Solution A (25mM 
NaOH, 0.2mM EDTA (pH ~12) for 1 hour at 95°C.  0.1mL of Solution B (40mM Tris-
HCL, pH ~5) was then added the samples are vortexed and centrifugated for 3 
minutes at approximately 10,000 RCF. Two microliters of mouse genomic DNA is 
then added to a PCR master mix containing the primers vPKfor-5’-
CAGAAGCAGTGTTACCTGTA-3’ and vPKrev-5’-ACATGGCGATACTCACATTC-3’. 
Immunoblots. Tissues that are to be used for the evaluation of protein 
expression are immediately flash frozen in an ethanol/dry ice bath following 
extraction. The frozen tissues are maintained at -80°C until processed. For 
processing, each tissue sample is homogenized in RIPA buffer containing protease 
and phosphatase inhibitors (Roche). To clarify, the samples are then centrifugated 
16,000 RCF for 15 minutes at 4°C. Protein expression is evaluated using the Pierce 
BCA protein assay. To evaluate vPK protein expression, equal amounts of protein 
(100 µg) were loaded per lane and resolved by SDS-PAGE and then transferred to a 
nitrocellulose membrane. Blots are then probed using a monoclonal vPK antibody 
and anti-rabbit secondary from Cell Signaling. 
Tissue preparation and flow cytometry. Mice were sacrificed by exposure to 
carbon dioxide and subsequent cervical dislocation. A single cell suspension was 
prepared from spleens by mashing the organ on ice with the top of a sterile syringe 
plunger in a 6-well dish containing cold DMEM. This suspension was then passed 
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through a 40-µm strainer. All procedures were carried out on ice. Cells were washed 
in cold PBS and incubated with ACK lysis buffer for 5 minutes at room temperature 
to lyse red blood cells. Cells were washed again with cold PBS to remove the lysis 
buffer. Cells were then resusupended in FACS buffer that contains PBS and 1% 
bovine serum albumin (BSA). Cells were counted and subsequently incubated with 
mouse Fc block (BD Biosciences, 553142) per the manufacturer’s instructions. Cells 
were then stained with fluorochrome-conjugated antibodies in FACS buffer at 
1e6/0.100 mL/reaction on ice for 30 minutes in the dark. After staining, cells were 
washed in FACS buffer 3X and resuspended in FACS buffer containing 1% 
formaldehyde. The fluorochrome-conjugated antibodies used for flow cytometry 
were purchased from eBioscience: CD8 PE (12-0081-83), CD4 FITC (11-0041-82), 
CD19 e450 (48-0193-80), CD3 APC (17-5993-80), CD21 PE (12-0211-81), CD23 
FITC (11-0232-81), live/dead e780 (65-0865-14), IgM PE (12-5890-81), IgD APC 
(17-5993-80), B220 e450 (48-0452), GL-7 AF488 (53-5902-80), CD95 PE (12-0951-
81), CD86 FITC (11-0862), CD69 FITC (11-0691), CD44 e450 (48-0441). CD138 PE 
was from Biolegend 142503. Samples were processed and data acquired on a 
MACSQuant VYB (Miltenyi Biotec,). Data was analyzed using FlowJo software (Tree 
Star). 
Preparation of tissues for H&E staining. Tissues were collected in 10% 
buffered formalin. After 3-7 days, the tissues were placed in cassettes, washed with 
water for 10 minutes and then placed in 70% ethanol. The tissues were then 
paraffin-embedded, cut into 4 µm sections and placed on slides. The sections were 
then visualized at magnifications of 100X and 200X using a Leica DMLS 
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microscope. Images were acquired using the Leica DFC480 camera and associated 
Leica Firecam software.  
NP-KLH immunization. vPK heterozygous or WT littermate C57BL/6 mice 8-
12 weeks old were injected interperitoneally with 100ug NP-KLH precipitated in alum 
(1:1) or PBS control. Mice were sacrificed 10 days following immunization.  
Tissue extraction from old vPK transgenic and WT mice. Mice were 
sacrificed by exposure to carbon dioxide and subsequent cervical dislocation. Blood 
was collected in serum gel z1.1 tubes (Sarstedt). An ear biopsy was also collected 
for genotype confirmation. Lungs, liver, spleen, kidney, and mass were collected. 
Each tissue was divided into 3 pieces for snap freeze, RNAlater (Qiagen) and 10% 
buffered formalin preservation.  
Statistical analysis. All statistical analysis was completed using GraphPad 
Prism. 
 
 
CHAPTER 5. SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS 
GENERAL SUMMARY 
The overarching objective of my dissertation was to determine how KSHV and 
its viral proteins alter host cellular proteins and signaling pathways that contribute to 
oncogenesis.  
Over the course of completing the research for this dissertation, I had the 
opportunity to work on a translational research project that involved testing the 
efficacy of two drugs in vitro and in vivo. The outcome of this project has clinical 
value to the medical and scientific community. In our experiments, we found that 
dual inhibition of two major cell survival pathways, PI3K and MAPK was no more 
effective at killing tumor cells than inhibition of the PI3K pathway alone. This is in 
contrast to solid tumors such as in breast cancer where dual PI3K and MAPK 
inhibitors were shown to be more effective [117]. Although ours is a negative result, 
our data informs practitioners and scientists and guides them on the development of 
future NHL therapies. 
 The main objective for my second project was to provide additional insight into 
how the KSHV K1 protein promotes oncogenesis. Our lab had already reported that 
K1 activates the PI3K pathway, resulting in the inhibition of apoptosis [51]. We 
thought that there might be additional mechanisms by which K1 promotes cell 
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survival. My work confirmed mass spectrometry results indicating that K1 associates 
with AMPKγ1, and that this association is important for K1’s survival advantage 
following exposure to metabolic stress. This project not only added to our knowledge 
about K1, it also began to explore the role of AMPKγ1 as a pro-survival factor during 
KSHV infection. Some very interesting future research projects should involve 
understanding AMPK biology during KSHV latent and lytic infection. 
My third project objective was to evaluate vPK expression in vivo. During the 
generation of the vPK mouse lines, our lab was trying to understand the impact of 
vPK in vitro. At that time, we had begun to realize that vPK was an S6KB1 mimic in 
that it phosphorylates some of the same proteins as S6KB1 such as ribosomal 
protein S6 and have since published that data [62]. We found that naïve vPK mice 
have a mildly activated immune system that resembles the immune response of 
immunized WT mice. We also observed for the first time in the herpesvirus field that 
vPK expression in vivo promotes the development of lymphomas in aged-vPK mice. 
This finding may also have relevance in our understanding of cellular S6KB1 
biology.  
Although the projects that compose my dissertation appear fairly diverse in 
terms of the techniques and models employed; the overall objective, which ties 
these projects together, is to understand how KSHV and its viral proteins alter host 
cellular proteins and signaling pathways that then contribute to oncogenesis.  
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DUAL INHIBITION OF THE PI3K/MTOR AND MAPK PATHWAYS IN NON-
HODGKIN LYMPHOMA 
The objective of my first project was to evaluate the effectiveness of dual 
inhibition of the PI3K and MAPK pathways in NHL, which includes latently KSHV-
infected PEL. Because both the PI3K and MAPK pathways are active in PEL and 
other non-Hodgkin lymphomas and dual inhibition of these pathways has been 
shown to be effective at reducing tumor burden in solid tumor models [117], we 
sought to evaluate the effectiveness at dual inhibition in NHL. The PI3K pathway 
inhibitor, NVP-BEZ235, inhibits two nodes of this pathway, PI3K and mTOR, making 
it a very effective PI3K pathway inhibitor. Our lab had already shown that NVP-
BEZ235 could reduce PEL cell proliferation and tumor burden in a PEL xenograft 
model [80] indicating that the PI3K pathway is important for PEL survival.  
Thus, we proceeded to evaluate dual inhibition of the PI3K and MAPK 
pathways by treating NHL cell lines with a constant concentration of NVP-BEZ235 
and a titration of the MAPK pathway inhibitor, AZD6244. By inhibiting MEK1/2 and 
downstream ERK1/2, AZD6244 targets only one arm of the MAPK pathway. We 
evaluated cell proliferation by MTS assay. In all of the cell lines that we evaluated, 
AZD6244 was simply not very effective at killing these cells. We also evaluated dual 
inhibition of these pathways in vivo by treating with both inhibitors and determining 
tumor size over time in a xenograft model of follicular lymphoma, an NHL. As we had 
observed in vitro, dual inhibition of these pathways was not as effective as PI3K 
pathway inhibition alone. The conclusion of this project is that NHL cells are more 
reliant on the PI3K pathway for survival than the MAPK pathway.  
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 Because AZD6244 inhibits MEK1/2, which is only one arm of the MAPK 
pathway, future efforts may involve the inhibition of one of the other arms of the 
MAPK pathway such as the p38 or JNK arms, depending on the activity levels in 
NHL. We may also have to pursue a more individualized approach since there 
appear to be differences in response among the various NHL cell lines suggesting 
that these pathways may be differentially active in each NHL line.  
 
THE KSHV K1 PROTEIN MODULATES AMPK FUNCTION TO ENHANCE CELL 
SURVIVAL 
For my second project, we wanted to understand whether K1 modulated cellular 
proteins in addition to the PI3K pathway to promote oncogenesis. We completed a 
tandem affinity purification of K1 or EV, and identified K1-associating proteins by 
mass spectrometry. In addition to HSP90, which we had already identified as a K1-
associating protein and thus supported our current mass spectrometry result [145], 
we found that K1 associates with AMPKγ1.  
We initially investigated the impact of AMPK activity on the PI3K pathway in the 
context of K1 expression. In replete conditions, the PI3K/mTOR pathway is active, 
and when cells are starved, the pathway is inhibited by active AMPK [86]. When we 
serum starve cells for about 8 hours and then evaluate phosphorylated S6K in EV 
and K1-expressing cells, we find that phosphorylated S6K levels are reduced in both 
EV and K1-expresssing cells compared to cells in replete conditions but the level of 
phosphorylated S6K is on average higher in K1 cells than EV. At the same time, we 
observe a slight increase in phosphorylated AMPK following serum starvation, in K1 
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expressing cells compared to EV. With longer periods of serum starvation such as 
around 24 hours, phosphorylated S6K can be remarkably reduced in both EV and 
K1-expressing cells. Overall, this data suggests that under certain circumstances, 
K1 maintains the activation of the PI3K pathway despite AMPK activation (Fig. 5.1). 
This may be beneficial for the virus since it allows infected cells to generate ATP, yet 
simultaneously activate protein synthesis to support viral protein production. 
  
 
 
Figure 5.1. K1 maintains PI3K pathway activation despite AMPK activation. 
Next, we used cells infected with WT K1 containing virus and K1 mutant 
recombinant viruses [182]. We observed that upon serum starvation, particularly 
after 48 and 72 hours, the KSHV- K1 WT infected cells had a survival advantage 
compared to KSHV-K1 mutants (Fig. 3.1). Knowing that AMPK is a major metabolic 
regulator in the cell and it becomes activated in response to various cellular 
stresses, we suspected that AMPK has a role in K1-mediated cell survival.  
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We next found that K1 expression rendered cells less sensitive to cell death 
following AMPK inhibition and that the association between K1 and AMPKγ1 
appears important for K1’s survival advantage following exposure to metabolic 
stress. We also observed increased AMPK activity in K1-expressing cells compared 
to EV when starved of serum and growth factors and treated with an AMPK inhibitor. 
Thus, we suggest that K1 mediates cell survival following exposure to nutrient 
deprivation via its association with AMPK.  
However, we do not suggest that the increase in AMPK activity in K1-
expressing cells translates fully to the survival advantage observed in KSHV K1 WT 
cells (Fig. 3.1). AMPK has previously been reported to have kinase-independent 
functions [183, 184]. Therefore, in addition to facilitating AMPK activity under specific 
cellular conditions, K1 could modulate kinase-independent activity of AMPK. Others 
have suggested that when AMPK is in an active conformation, it inhibits factors such 
as PPARα and PPARγ [183]. The inhibition of these factors appears to be 
independent of kinase activity. Thus, binding of K1 to AMPKγ1 could facilitate AMPK 
independent activity. We observed that K1-expressing cells are less sensitive to 
compound C treatment as observed by improved cell viability compared to EV (Fig. 
3.3A). Association of K1 and AMPKγ1 may promote AMPK stability thereby 
facilitating kinase dependent and independent activity.  
Although AMPK has historically been thought of as a tumor suppressor, there is 
accumulating evidence to suggest that AMPK promotes metabolic adaptation in 
tumor cells and in this way, promotes tumor cell survival. Several mechanisms for 
how AMPK promotes tumor cell survival have been proposed. Jeon et al. found that  
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nicotinamide adenine dinucleotide phosphate (NADPH) production was impaired 
when cells were deprived of glucose, and that by activating AMPK, homeostatic 
levels of NADPH could be maintained and prevent cell death [185]. Activated AMPK 
inhibited acetyl-CoA carboxylases ACC-1 and ACC-2. Inhibition of ACC-1 and ACC-
2 resulted in inhibition of fatty acid synthesis, which consumes NADPH and 
increased fatty acid oxidation, which results in the production of NADPH [185]. 
Through the control of these processes, AMPK maintains NADPH levels and 
prevents H2O2-induced cell death [185].  
Somewhat in support of this idea, Buzzai et al. found that Akt expressing cells 
where susceptible to cell death when deprived of glucose [151]. They found that 
cells could be rescued from death by activating AMPK, which promoted fatty acid 
oxidation and inhibited cell death. Cell survival was not dependent on translation or 
lipid synthesis [151].  
To explore the possibility that K1 may mediate cell survival following exposure 
to stress via AMPK’s regulation of fatty acid oxidation, future experiments could 
involve the evaluation of fatty acid oxidation in EV and K1-expressing cells under 
normal and various conditions of stress as well as with and without AMPK activators 
and inhibitors.  
Many questions related to this project still remain. AMPK has multiple subunits 
and isoforms as previously mentioned, and we still lack a clear understanding of the 
specific functions of AMPK when composed of different combinations of isoforms. 
Because AMPK does respond to various types of cellular stress and is a major 
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metabolic regulator of energy homeostasis, we suspect that AMPK will have different 
roles throughout the life cycle of KSHV.  
Future efforts to evaluate K1-mediated cell survival may involve the 
investigation of some of the other K1-associating proteins that were identified by 
mass spectrometry.  
THE KSHV ORF36 PROTEIN KINASE AUGMENTS TUMORIGENESIS IN A 
MOUSE MODEL SYSTEM 
My third project involved the evaluation of ubiquitous expression of vPK or 
ORF36 in vivo. We started the initial characterization by simply evaluating the basic 
immune cell subsets in the spleen. Because the phenotype was somewhat subtle, 
we had to complete additional experiments, in which spleens from more mice of 
each line were evaluated. The flow cytometry panel was fine-tuned each time based 
on the results from previous experiments.  
Because the vPK mice had mildly activated immune systems, we sought to 
exacerbate the immune response in naïve vPK mice by administering a primary 
immunization of NP-KLH. NP-KLH administration did not exacerbate the immune 
response in vPK transgenic mice. We observed approximately equal numbers of B 
and T cell subsets in vPK mice that had been immunized with NP-KLH compared to 
vPK mice that had been administered PBS. The salient finding of this experiment is 
that the vPK immune response following PBS injection was similar to the immune 
response of immunized WT mice.  
As we characterized the immune response using 8-12 weeks of age mice, we 
allowed a cohort of vPK and littermate controls to age. We sacrificed these mice in 
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small numbers as they reached about 18-24 months of age or as necessitated due 
to health issues or an observed mass. We observed that there was greater tumor 
prevalence in vPK mice compared to age-matched controls. The tumors are 
composed of lymphocytes, and appear to be lymphomas based on the preliminary 
review of H&E stained tumor sections by pathologists. We are currently determining 
clonality by determining VDJ recombination and the ratio of kappa:lambda light chain 
in tumors.  
Some of the vPK mice exhibited lymphoproliferation in various organs such as 
the lung, spleen, liver and kidney; and yet were not classified as having overt 
morphologic lymphoma. Thus, the vPK transgenic mice may have a spectrum of 
progressive stages that lead from lymphoproliferation to neoplasia. To understand 
the progression to lymphoma, future work should involve harvesting cohorts of vPK 
and control mice at different time-points as they age for the classification of 
lymphoproliferation, pre-malignant lesions and malignant lesions. 
The paradigm of KSHV pathology has been that the episodic reactivation of 
KSHV results in the production of angiogenic and inflammatory factors that promote 
the survival of the KSHV latently infected cell, which then spurs oncogenesis. This 
paradigm is supported by some of the in vivo studies. The expression of latent 
genes in vivo can directly result in the development of tumors such as those 
observed in mice expressing v-FLIP in stage-specific B cells [42]; whereas in vivo 
expression of the lytic gene ORF74, which is a constitutively active G-protein 
coupled receptor (GPCR) develop tumors that most likely arise from paracrine 
mechanisms since only some of the tumor cells express GPCR, and there is the 
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presence of inflammatory cytokines and angiogenic factors in these models  [186-
188].   
Viral PK, which is a lytic protein, may promote oncogenesis via direct and 
indirect mechanisms. As a kinase, vPK expression in vivo may simultaneously 
directly and indirectly instigate lymphogenesis by activating substrates that are 
involved in cell growth, proliferation and cell cycle [57, 62], and by modulating 
substrates resulting in the production of cytokines that support malignant B cell 
survival. Future efforts will involve exploration into the mechanisms by which vPK 
facilitates lymphogenesis.  
Because the vPK mouse expresses vPK ubiquitously, our mouse model system 
explores the extreme of vPK expression. In a KSHV infected individual, KSHV 
infects a subset of cells out of the total number of cells in the body and then only a 
subset of those cells would express vPK. Thus, our model does not recapitulate 
human KSHV infection, but for the first time, we are able to evaluate the pathology of 
in vivo vPK expression and the changes in cell signaling pathways that lead to the 
pathology.  
 
In conclusion, the PI3K pathway is important for KSHV-infected cell survival. 
The viral proteins K1 and vPK promote the activation of this pathway by different 
mechanisms. K1 activates the PI3K by activating PI3K via its ITAM. At the same 
time, we found that K1 associates with AMPK in the perinculear area of the cell, 
promotes cell survival following long periods of metabolic stress, and maintains 
activation of the PI3K pathway despite AMPK activity. Viral PK phosphorylates 
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proteins downstream in the PI3K pathway such as S6 protein and eIF4E. By 
maintaining the activity of this pathway, KSHV promotes protein synthesis and cell 
survival; on the other hand, aberrant activation of this pathway contributes to KSHV 
oncogenesis (Fig. 5.2). 
 
Figure 5.2. The KSHV viral proteins K1 and vPK modulate the PI3K pathway.  
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